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Abstract
A series of eleven different nickel Schiff base complexes was synthesized by
a two-step procedure. Initially ethylenediamine, phenylenediamine or meso1,2-diphenylethylenediamine

was

reacted

with

either

2,3-

or

2,5-

dihydroxybenzaldehyde in the presence of Ni(II) to afford six novel
dihydroxylated nickel Schiff base complexes. Five of these complexes were
then successfully reacted with 1-(2-chloroethyl) piperidine hydrochloride to
form a series of derivatives featuring two appended ethyl piperidine moieties.
All new complexes were characterised using 1D and 2D nuclear magnetic
resonance (NMR) spectroscopy, elemental microanalysis and in some
instances electrospray ionisation mass spectrometry (ESI-MS). The solidstate structures of three nickel complexes (5), (8) and (10) were determined
by single crystal X-ray crystallography, and revealed that the coordination
geometry around the nickel ion was square planar in each case.
The ability of the nickel complexes containing appended ethyl piperidine
groups to bind to a double-stranded 16mer DNA molecule, and a
tetramolecular DNA quadruplex, was investigated using ESI-MS and circular
dichroism (CD) spectroscopy. The results of these studies, as well as those
performed simultaneously using a series of previously reported analogues
prepared

by

the

same

synthetic

pathway,

but

with

2,4-

dihydroxybenzaldehyde as one of the initial reactants, enabled the effect of
varying the position of the ethyl piperidine groups on DNA-binding properties
to be explored. Generally, it was found that changing the position of the ethyl
iii

piperidine groups had only a small effect on binding affinity towards either
type of DNA molecule. In most cases there was good agreement between
orders of relative binding affinity towards a given DNA molecule determined
using the two spectroscopic techniques. On some occasions, however, the
results of binding studies conducted using ESI-MS and CD spectroscopy
diverged significantly. This may have been the result of the two methods
showing different sensitivities towards different aspects of the metal
complex/DNA interaction, and the varying stabilities of the non-covalent
complexes formed in these systems, to the gas phase environment of the
ESI mass spectrometer or to the solution phase used in CD experiments.
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CHAPTER 1

INTRODUCTION

1.1 Historical overview of anticancer drugs
Over the years, several treatment options for cancer have been developed.
These comprise surgery, radiotherapy and chemotherapy, as well as
combinations of all three approaches. Cancer treatment based on surgery or
radiotherapy cures only about half of the cancer cases, and then may only
prolong the lives of patients. The aim of most chemotherapeutic treatments is
to kill tumour cells through inhibition of cell division. Accordingly, many
cytotoxic anticancer drugs have been developed through this approach.
Deoxyribonucleic acid (DNA) is well known as the intracellular target for a
wide range of compounds which exhibit antibacterial, antiviral and anticancer
properties.1 The interaction of anticancer drugs with DNA molecules,
enzymes and also some proteins may cause inhibition of cellular division
mechanisms, eventually leading to cancer cell death. Cytotoxic agents can
damage DNA either directly or indirectly. Direct damage is caused through
disruption of DNA replication, while indirect damage is caused through
inhibiting the synthesis of the building blocks of DNA, such as folic acid, the
four heterocyclic bases, or the corresponding nucleotides. Nitrogen mustards
are examples of anticancer drugs that damage DNA directly, while folic acid
analogues are examples of anticancer drugs that damage DNA indirectly. 2-6
During the last few decades numerous compounds with anticancer activity
have been investigated, however many of them cannot be used clinically due
to their toxic side effects and lack of specificity. In order to be potentially
1

useful as an anticancer agent, a chemical compound must exhibit a high
degree of selective cytotoxicity towards cancer cells, as well as produce few
side effects when administered to patients.
Initially, the discovery of most anticancer drugs was based on the
experimental observation of the biological effects of large numbers of
chemical compounds or serendipitous discoveries, rather than knowledge of
their mechanisms of biological action. Despite this, some chemical
compounds have been successful in curing or prolonging the survival of
many cancer patients.7 Nitrogen mustard derivatives, folic acid analogues
and platinum complexes are just some examples of a wide range of chemical
compounds that have been used successfully as anticancer drugs in recent
decades, and continue to be used in the clinic.
The anticancer activity of the mustards was first discovered in 1935, when
the ability of mustard gas to inhibit the transplantation of tumours in animal
models was reported.8 This anticancer activity attracted more attention when
soldiers died as a result of their exposure to sulfur mustard during the
Second World War. It was observed that sulfur mustard caused massive
damage to bone marrow and lymph nodes in gas-exposed persons.9-11 The
toxic effect on the lymphatic system suggested a possible use of mustards as
anticancer drugs for treatment of lymphomas and leukaemias. Although
sulfur mustard was highly toxic when used in cancer therapy, it led to the
development of a series of analogues known as the nitrogen mustards. In the
early 1940s, Goodman and Gilman examined the potential therapeutic
effects of nitrogen mustard (mechlorethamine, Figure 1.1a) on a transplanted
2

lymphoid tumour. After using it in clinical trials on patients with non–
Hodgkin’s lymphoma and severe airway obstruction, marked regression was
observed.9,12,13 Unfortunately, treatment with mechlorethamine resulted in
severe side effects. This led to the development of chlorambucil and
melphalan (Figure 1.1b and c, respectively) which are widely used for the
treatment of lymphoma, leukaemia and ovarian carcinoma. 14

Figure 1.1: The structure of nitrogen mustard and some derivatives; a)
nitrogen mustard (mechlorethamine); b) chlorambucil, and c) melphalan.

Nitrogen mustards were used as anticancer agents long before their
mechanism of action was understood. It has since been found that they
induce cell death by preventing the normal sequence of DNA replication,
through interstrand cross-linking of DNA.2-4 DNA was not identified as the
target of the mustards until after Watson and Crick proposed their model for
the structure of DNA in 1953.15,16 Cross-linking the two DNA strands blocks
DNA replication by preventing strand separation, as well as bending the
DNA, leading eventually to cell death.3,17

3

After the discovery of the effect of folate deficiency on bone narrow, a series
of folic acid analogues including aminopterin and methotrexate were
developed (Figure 1.2). Later, these folate antagonists were administered to
children with leukaemia, and it was found that they can induce remission.18,19
Methotrexate was also used successfully to treat metastatic cancer in 1956.20
Aminopterin and methotrexate were used as chemotherapeutic agents long
before their mechanism of action was reported by Osborn et al. in 1958.5,6
Both are antimetabolites that act through inhibiting dihydrofolate reductase, a
folate-requiring enzyme needed for DNA replication. This results in
interference with folate synthesis, eventually leading to cell death.5,6

Figure 1.2: Structure of some folic acid analougues used clinically as
anticancer agents: a) aminopetrin, and b) methotrexate.

4

Over the years, many other anticancer drugs which inhibit cell growth and/or
affect the integrity of DNA have been developed. The ongoing design and
synthesis of metal-based anticancer drugs stems from the serendipitous
discovery

of

the

anticancer

properties

of

cisplatin

(cis-

(diamminodichloro)platinum(II)) (Figure 1.3a) by Rosenberg et al.21-23
Cisplatin binds covalently to DNA predominantly via intrastrand cross-links
with the purine bases adenine and guanine. This process involves the two
chlorine atoms of cisplatin being replaced by the N7 atoms of two adjacent
purines on the same DNA strand.24-27

Figure 1.3: Structure of some platinum anticancer complexes: a) cisplatin; b)
carboplatin, and c) oxaliplatin.

The binding of cisplatin to DNA results in bending and unwinding of the
double helix, ultimately leading to the cell undergoing apoptosis.28-33 Cisplatin
is highly cytotoxic towards a variety of tumours such as testicular, ovarian,
head and neck, and bladder carcinomas, as well as lymphoma. 34-41
Unfortunately, cisplatin does not exert its cytotoxicity selectively towards
cancer cells, resulting in severe side effects including nausea, ear damage,
vomiting, nephrotoxicity, neurotoxicity, and emetogenesis.42-44 As a result of
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attempts to overcome these toxic side effects, a number of less toxic
platinum drugs have been developed. These include carboplatin (Figure
1.3b), which is effective for the treatment of ovarian cancer, and oxaliplatin
(Figure 1.3c), which is used to treat colon cancer.
Increased understanding of cancer biology, developments in molecular
biology techniques, and elucidation of the complete sequence of the human
genome have all led to the development of new therapeutic approaches
known as targeted therapies.45 Targeted therapies are based on designing
drugs that interfere with the activity of a specific biological target or process
which is critical for cancer cell survival, such as a gene, enzyme or protein.45
In the recent years, many drug targets have been identified for targeted
therapy approaches, including DNA polymerases and topoisomerases,
kinase signalling pathways, nuclear hormone receptors in breast and
prostate cancer, and telomerase. Since the therapeutic activity of many
anticancer drugs is a result of their binding to DNA, understanding the
structure and mechanism of replication of nucleic acids has played a
significant role in the development of targeted therapy.

1.2 Duplex DNA
DNA, or deoxyribonucleic acid, is a hereditary material that is present in the
vast majority of living organisms. DNA is the main constituent of
chromosomes, and its genetic information is used to synthesise the proteins
that are required for numerous biological functions and processes.46,47
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DNA is a polymer made from repeating units called deoxyribonucleotides that
link together through phosphodiester bonds. Each deoxyribonucleotide is
composed of deoxyribose sugar, a phosphate group, and a nitrogenous
base, which could be either a pyrimidine (cytosine (C) or thymine (T)), or a
purine (adenine (A) or guanine (G)) (Figure 1.4).48 The nitrogenous base is
linked to deoxyribose forming a nucleoside. The nucleosides are joined
together by phosphate groups that form phosphodiester bonds with the 5hydroxyl group on one nucleoside and the 3-hydroxyl group on the
neighbouring nucleoside. This linkage results in the formation of a single
DNA strand.

Figure 1.4: The chemical structures of the nitrogenous bases present in
DNA.

B-DNA is the most common form of double-stranded DNA (dsDNA) that is
found in biological systems, and its structure was first determined by Watson
and Crick in 1953.15 By using results obtained from X-ray diffraction, they
determined that this form of DNA is an anti-parallel, right-handed double
helical molecule, with the two polynucleotide chains held together by
hydrogen bonds between the pyrimidine and purine bases on opposite
strands (base pairing) (Figure 1.5a).15 Base pairing occurs when adenine
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residues on one strand form two hydrogen bonds with thymine residues on
the opposite strand, and guanine residues form three hydrogen bonds with
cytosine residues (Figure 1.5b). In addition to base pairing, interactions
between the π electron clouds of the bases contribute to the overall stability
of B-DNA.

Figure 1.5: a) Schematic illustration of the structure of double-stranded DNA.
b) Structures of the two types of Watson-Crick base pairs present in B-form
DNA.

There are two less common forms of duplex DNA, known as A- and Z-DNA
(Figure 1.6). In low humidity environments B-DNA can convert to A-DNA,
which also has a right handed helical structure.49 Duplex DNA can also adopt
the Z-form structure in solutions with high salt concentrations. 50,51 Z-DNA is a
left-handed double helix, and is wider and more compact than B-DNA.52
8

A-DNA

B-DNA

Z-DNA

Figure 1.6: The structures of A-DNA, B-DNA and Z-DNA. Adapted from
various references.53,54

It has been discovered that some proteins bind to Z-DNA with high affinity
and specificity, and that B-DNA can change to Z-DNA in the hippocampus of
brains of patients with Alzheimer’s disease.55 These findings suggest that the
Z-DNA conformation may play a biological role in a variety of cellular
functions.
As a result of the geometrical configuration of the bonds between the
deoxyribose sugar-phosphate backbone and the nitrogenous bases in the BDNA structure, two different sized grooves, the major and minor grooves,
form along the surface of the nucleic acid.46,56 A wide range of proteins,
oligonucleotides and metal complexes can bind to DNA through these
grooves.57 Since the major and minor grooves vary in their hydrogen bonding
characteristics, electrostatic potential, extent of hydration and size and
shape, it has been found that some molecules prefer to bind in one groove
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over the other. For instance, it was observed that small organic molecules
with a crescent shape act as minor groove binders, while proteins and
oligonucleotides act as major groove binders.58 The interactions between
DNA and groove binding molecules include van der Waals, electrostatic and
hydrophobic interactions, as well as hydrogen bonding with the DNA base
pairs.59-62
The naturally occurring antibiotics distamysin and netropsin (Figure 1.7) are
examples of dsDNA minor groove binders.60 It has been found that these
molecules prefer to interact with AT-rich DNA sequences. This binding
preference is attributed to the fact that AT-rich regions are less sterically
demanding, and able

to participate in strong electrostatic binding

interactions.61 On the other hand, the interaction of minor groove binders with
GC-rich dsDNA sequences is inhibited for steric reasons, owing to the
formation of hydrogen bonds between the amino group of the guanines and
the carbonyl oxygen atoms of cytosine residues in GC base pairs.59
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Figure 1.7: Structure of some DNA minor groove binders: a) distamycin, and
b) netropsin.

The structure of double helical DNA also offers an additional binding site to
the minor and major grooves. Some small aromatic molecules can insert
themselves and stack between adjacent base pairs within the DNA double
helix.59 Such molecules are known as intercalators. Intercalative binding is
stabilized by hydrogen bonding, charge transfer and hydrophobic interactions
between the aromatic intercalator and the DNA base stack. 63 The
interactions between the π-orbitals of the intercalating ligand and those of the
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base pairs widen the gaps between the base pairs, resulting in unwinding
and bending of the DNA molecule, and an increase in its length.47,56,64
The DNA stain ethidium bromide (EtBr) and the anticancer drug daunomycin
(Figure 1.8) are examples of organic intercalators.47,65 The binding of
daunomycin is further stabilized by the formation of hydrogen bonds between
the hydroxyl group of the daunomycin glycone ring and an adjacent guanine
base. These hydrogen bonds were found to play a significant role in the
biological activity of daunomycin.65 Many intercalators have also been found
to possess a positive charge, which facilitates electrostatic binding
interactions with dsDNA.66,67

Figure 1.8: Structure of some organic intercalators: a) ethidium bromide, and
b) daunomycin.

1.3 Quadruplex DNA and telomeres
In addition to the double helical structures, certain DNA sequences can form
multistranded helices such as quadruplexes (G-tetraplexes), and i-motifs (itetraplexes) which have been identified by some crystallographic and NMR
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studies.68-72 In particular, G-quadruplex DNA has attracted considerable
interest in recent years because of its ability to form in telomeric DNA
sequence, and also act as an inhibitor for telomerase, the enzyme
responsible for telomere maintenance.73-75
Telomeres are found at the ends of linear eukaryotic chromosomes, and are
comprised of telomeric DNA bound to a variety of proteins. Telomeric DNA is
composed

of

tandem

repeats

of

noncoding

double-stranded

base

sequences, and with a guanine-rich strand forming a protruding 3 singlestrand overhang.69 For instance, repeats of the sequence d(TTAGGG)
constitute human telomeres, while repeats of the sequence d(TTTTGGGG)
are found in the telomeres of the protozoa Oxytricha novat.69,76
Telomeres play a vital role in cell growth and proliferation, as they protect
chromosomes from degradation and fusion with each other.69 Their role is to
maintain the structural integrity of chromosomes by protecting their ends from
being recognized as double-strand breaks during cell division.77,78 Normal
somatic cells progressively lose telomeric repeats during cellular division,
with the chromosomes shortening by 50–200 bases after each round of DNA
replication.77 Losing telomeric DNA means that important genetic information
is not lost with each round of cellular division. However, when the length of
telomeric DNA decreases to a critical length, dsDNA cannot replicate
anymore, and the cell enters a senescent state, after which it undergoes
apoptosis, and dies.77 This process can be prevented by telomerase, a
ribonucleoprotein enzyme made of protein and RNA subunits. Its biological
role is to maintain telomere length by adding G-rich DNA repeat sequences
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onto the 3′-end of telomeric DNA.77,79 Telomerase activity is typically tightly
regulated during development, and exhibits minimal activity in somatic cells,
which leads to a gradual shortening of telomeres as the organism ages.
In contrast, telomerase has been found to be much more active in germ cells
and human tumours.77 Stabilization of telomere lengths by telomerase
contributes to more than 90% of human cancer cells effectively exhibiting
cellular immortality.80,81
In vivo, it has been shown that the single-stranded G-rich overhangs of
telomeres are susceptible to folding into a variety of guanine-rich DNA
structures known as G-quadruplexes.78,82 This telomeric quadruplex DNA has
attracted widespread interest as a therapeutic target for cancer treatment.83
G-quadruplexes are made from G-rich DNA sequences arranged to form
multiple stacked guanine tetrads held together by π-stacking interactions and
stabilized by monovalent cations (such as potassium or sodium) that are
located between each pair of G-tetrads (Figure 1.9a).69,84 A G-tetrad is a
square planar array of four guanine bases held together by eight Hoogsteen
hydrogen bonds (Figure 1.9b).78,69
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Figure 1.9: a) a schematic structure of a G-quadruplex formed by stacking of
G-tetrads from four parallel DNA strands; b) structure of a G-tetrad featuring
the Hoogsteen hydrogen bonding. (M+ = Na+ or K+).

G-Quadruplex DNA exhibits a variety of three dimensional structures that are
formed through either folding of a single DNA strand (intramolecular folding),
or the association of two or four strands of DNA (intermolecular
association).The structural diversity of G-quadruplexes is due in part to the
range of strand orientations (parallel, antiparallel or hybrid) observed (Figure
1.10). These different topologies depend on a wide variety of factors, such as
loop length, DNA strand sequence, number of individual G-tetrads, and the
surrounding environmental conditions.84-88 The different topologies of Gquadruplex DNA provide access to a variety of chemical functional groups
that can be targeted by small molecules.
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Figure 1.10: Schematic illustration of some different qDNA topologies: a)
Intermolecular parallel tetramolecular G-quadruplex; b) intermolecular
antiparallel bimolecular G-quadruplex; c) intramolecular antiparallel
unimolecular G-quadruplex. Adapted from various references.89,90

In addition to their occurrence in telomeric regions, guanine-rich DNA
sequences that are susceptible to adopting G-quadruplex DNA structures are
found in other locations in the human genome, including chromosomes,
centromeres, fragile X syndrome repeats, the c-myc gene, retinoblastoma
susceptibility genes, and human insulin genes.89,91-93 This indicates that Gquadruplex structures may also have a role in other diseases besides cancer.
The formation of G-quadruplexes in these regions also means they may be
involved in various biological functions such as regulation of transcription and
translation, DNA recombination, and replication of DNA stands.68,94-99
However, during the last few years the majority of research has focused on
the formation and stabilization of G-quadruplexes in telomeres.100-102
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Inhibition of telomerase activity in cancer cells has attracted attention as a
new approach to cancer treatment. It has been shown that the folding of
telomeric DNA into G-quadruplex structures impedes telomerase from
elongating telomeres.82 Some studies in cancer cells have shown that small
molecules which bind to and stabilize G-quadruplexes have caused damage
to the telomeres as a result of their dissociation from single-stranded DNA
(ssDNA) templates.40,73-75,82,103,104 It has been shown that such molecules
bind to quadruplex DNA either by intercalation between the G-tetrads or
through stacking with terminal G-tetrads.105 A wide range of qDNA-binding,
small

aromatic

molecules

have

been

investigated.

These

include

anthraquinones (e.g. 2,6-diamidoanthraquinone), acridines (e.g. BRACO19=
N-[9-[4-(dimethylamino)anilino]-6-(3-pyrrolidin-1-ylpropanoylamino)acridin-3yl]-3-pyrrolidin-1-ylpropanamide), porphryins (e.g. TMPyP4= tetra(N-methyl4-pyridylporphine) and natural compounds (e.g. telomestatin) (Figure
1.11).74,106-110
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Figure 1.11: Structures of some compounds that bind to qDNA: a) 2,6diamidoanthraquinone; b) TMPyP4; c) BRACO19, and d) telomestatin.

NMR

studies

conducted

by

Sun

et

al.

revealed

that

2,6-

diamidoanthraquinone binds to a parallel four-stranded G-quadruplex through
intercalation between the G-tetrads.74 Further studies conducted by
Wheelhouse and co-workers showed that the porphyrins like TMPyP4 could
bind to both parallel and anti-parallel q-DNA intercalatively.73,89,111 In addition,
research has shown that both the acridine BRACO19 and the natural product
telomestatin can bind to quadruplex DNA and act as telomerase
inhibitors.103,112-114 All these studies have concluded that the binding of small
molecules to G-quadruplex DNA is affected by various factors including their
overall charge, the length of any side chains present, and hydrogen bonding
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substituents.74 Some known double-stranded DNA binding compounds such
as distamycin, daunomycin and ethidium bromide have also been found to
bind to G-quadruplex DNA.115,116 Compounds that bind to both doublestranded DNA and G-quadruplex DNA are consequently cytotoxic at the
concentrations required to inhibit telomerase.104 Therefore, it is important to
develop new compounds that exhibit high binding affinities and selectivity for
quadruplex DNA, over duplex DNA.

1.4 Metal complexes that bind to DNA
During the last few decades there has been increased interest in transition
metal complexes as potential anticancer and antibacterial therapeutics. 117
Some metal complexes have been shown to interfere with DNA replication,
DNA transcription and apoptosis, meaning they can be used to damage DNA
and induce cell death.43,118,119 It is well known now that the biological activity
of some metal complexes is due to their ability to bind to DNA.30,66,120 The
great diversity in structures and size of transition metal complexes, as well as
their electrochemical and photophysical properties, makes them attractive as
selective DNA binding reagents.56,121,122 Therefore, the DNA binding
properties of a number of metal complexes have been investigated. A large
proportion

of

these

complexes

contain

ruthenium(II),

rhodium(III),

platinum(II), platinum(IV), and titanium(IV), and their DNA-binding behaviour
has been extensively investigated both in vitro and in vivo. Much attention
was initially directed to square planar and octahedral complexes containing
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inert metal ions such as platinum(II), rhodium(III) and ruthenium(II) with
bidentate or tetradentate aromatic heterocyclic ligands.121 These metal
complexes are non-covalent DNA-binding agents that act as either groovebinders or intercalators.121

1.4.1 Metal complexes that bind to dsDNA
Almost 35 years ago the Sigman group demonstrated that [Cu(phen)2]+,
(phen = 1,10-phenanthroline) (Figure 1.12a) binds to DNA non-covalently by
interacting with the DNA minor groove, and functions as a synthetic DNA
nuclease.123 Since this demonstration many other studies have established
that most mononuclear, inert transition metal complexes especially those
bearing aromatic ligand bind in the minor groove of DNA. This includes
platinum complexes such as [Pt(en)2]2+ (en= 1,2-diaminoethane), (Figure
1.12b), and the square planar nickel(II) metallopeptide Ni(II)*Lys-Gly-His
(Figure 1.12c), which was found to selectively associate with the dsDNA
minor groove at A/T rich sites.124,125 Although most mononuclear, inert
transition metal complexes act as minor groove binders, it was found that
cobalt(III) ammine complexes such as [Co(NH3)6]3+ and [Co(en)3]3+ (Figure
1.12d and e, respectively) selectively interact with GG sequences in the
major groove of dsDNA.126,127 It has been proposed that the binding
preferences of metal complexes for the major or minor groove at different
base sequences is due to the availability of more favourable van der Waals
interactions and electrostatic potentials, coupled with opportunities for
specific hydrogen bonding interactions at these regions.
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Figure 1.12: Examples of mononuclear metal complexes that bind to dsDNA:
a) [Cu(phen)2]+; b) [Pt(en)2]2+; c) Ni(II)*Lys-Gly-His; d) [Co(NH3)6]3+, and e)
[Co(en)3]3+.

While most of these complexes were found to be groove binders, a wide
variety of metal complexes have also been found to intercalate with dsDNA.
For example, square planar platinum(II) complexes containing an aromatic
heterocyclic ligand such as terpy, phen, bipy, or phi, (terpy = 2,2′:6′2′′terpyridine, phen = phenanthroline, bipy= 2,2′-bipyridine, phi= 9,10phenanthrenequinone), have been shown to bind to double-stranded DNA
noncovalently by this mechanism.128-136 The square planar geometry of Pt(II)
complexes allows deeper insertion of attached intercalating ligands between
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base pairs than is possible with octahedral or tetrahedral complexes.129
[Pt(terpy)(SCH2CH2OH)]+, (Figure 1.13a), synthesised by Lippard and coworkers, was the first metal compound shown to bind to dsDNA by
intercalation.130 A single crystal X-ray diffraction study revealed that
[Pt(terpy)(SCH2CH2OH)]+ intercalated between the base pairs of double
helical DNA.131 It was shown to intercalate into calf thymus DNA (CT-DNA)
with a binding constant of 2x105 M-1, and to increase the length of the DNA
as well as stabilize it.132,133 Lippard and co-workers conducted further studies
to investigate the intercalative properties of other platinum complexes
including [Pt(bipy)(en)]2+ and [Pt(phen)(en)]2+ (Figure 1.13b and c). X-ray
diffraction and electrophoresis studies revealed that the planar ligands phen
and bipy help these complexes to intercalate and unwind DNA. 134-136 It was
concluded that the intercalative ability of metal complexes depends upon
various factors including the structural characteristics of the complex, DNA
composition and the ionic strength of the surrounding medium.137

Figure 1.13: Examples of platinum metallointercalators: a) [Pt(terpy)(SCH2CH2OH)]+; b) [Pt(bipy)(en)]2+; c) [Pt(phen)(en)]2+.
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Another study involving platinum intercalators was conducted by AldrichWright and co-workers. They examined the effect of a series of Pt(II)
complexes with the general formula [Pt(en)(Mexphen)]2+ (x = 1, 2 or 4) on
L1210 leukaemia cells. Their work revealed that the DNA affinity of these
complexes, and their activity towards the leukaemia cells, was affected by
the number and the position of the methyl groups on the phenanthroline
ligand.138,139 This result suggests that altering the ligand structure can
improve the binding affinity of metal complexes towards DNA.
Although platinum complexes were the initial focus of the majority of research
into metal anticancer complexes, a large amount of interest now focuses on
octahedral metallointercalators containing other transition metals. Interest in
the interactions of octahedral transition metal centres with DNA stems in part
from the discovery that [Ru(phen)3]2+ and related complexes can bind noncovalently and enantioselectively to DNA.122,140 This is partially attributable to
the greater size of the octahedral coordination sphere, which provides more
surface area for interactions with DNA and, therefore, potentially enhances
DNA binding selectivity. The binding properties of a wide variety of
octahedral rhodium and ruthenium complexes containing aromatic ligands
such as phen, phi, dppz, phzi, and eilatin (dppz = dipyrido[3,2-a:2,3c]phenazine,

phzi = benzo[a]phenazin-5,6-quinone

diimine, eilatin

dibenzo[b,j]dipyrido[4,3,2-de:2,3,4-gh][1,10]phenanthroline)

have

=

been

investigated.56,141,142
It has been found that metal complexes containing phen, phi or dppz bind to
duplex DNA via intercalation, by inserting these ligands to different extents in
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between two base pairs. In contrast, metal complexes containing phzioreilatin
bind via insertion, with this ligand displacing DNA bases out of the base
stack.56,141,142 Studies on chiral octahedral ruthenium(II) complexes such as
[Ru(DIP)3]2+ (DIP = 4,7-diphenyl-1,10-phenanthroline) (Figure 1.14a) showed
that

the

Δ-enantiomer

binds

more

tightly

to

B-DNA,

whilst

[Ru(phen)2(dppz)]2+ (dppz = dipyrido[3,2-a:2,3’-c]phenazine) (Figure 1.14b)
shows extremely high dsDNA binding affinity due to the expansive aromatic
surface area of the dppz ligand.143,144

Figure 1.14: Examples of some octahedral metallointercalators: a)
[Ru(DIP)3]2+, and b) [Ru(phen)2(dppz)]2+.

The inclusion of the highly intercalative dppz ligand in the coordination
sphere of a complex has been shown to generally enhance dsDNA binding
affinity.122,143,145 These studies concluded that the structure of the
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intercalating ligand present in a metal complex can affect its binding modes
and selectivity toward different DNA sequences. For example, one report by
Urathamakul and co-workers showed that the relative affinities of some
ruthenium complexes towards a dsDNA molecule decreased in the following
order: [Ru(phen)2(dppz)]2+> [Ru(phen)2(dpqMe2)]2+ (dpqMe2 = 6,7-dimethyl2,3-di(pyridin-2-yl)quinoxaline) > [Ru(phen)2(dpqC)]2+ (dpqc = dipyrido[3,2a:2’3’-c](6,7,8,9-tetrahydro)phenazine)
dipyrido[3,2-d:2’3’-f]quinozaline)>

>[Ru(phen)2(dpq)]2+

[Ru(phen)2(pda)]2+

diaminophenanthrene) > [Ru(phen)3]2+ (Figure 1.15).143
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Figure 1.15: Structures of dsDNA-binding Ru(II) complexes studied by
Urathamakul and co-workers: a) [Ru(phen)3]2+; b) [Ru(phen)2(dpq)]2+; c)
[Ru(phen)2(dppz)]2+;d) [Ru(phen)2(dpqC)]2+; e) [Ru(phen)2(dpqMe2)]2+; f)
[Ru(phen)2(pda)]2+.143

Another study conducted by Talib and co-workers found that the DNA binding
affinity of some octahedral nickel(II) complexes with different ligands followed
the

order

[Ni(phen)3]2+<

[Ni(phen)2(dpq)]2+<

[Ni(phen)2(dpqC)]2+<

[Ni(phen)2(dppz)]2+.144 These studies suggest that the binding affinity of
[M(phen)3]2+ complexes can be increased by replacing one phen ligand with
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other aromatic bidentate ligands which have an extended polycyclic
structure.
Other studies have investigated the effect upon DNA binding of changing the
identity of the metal ion present in a metallointercalator.146,147 For example,
Arounaguiri and co-workers examined the binding affinity of complexes with
the general structure [M(phen)2(dppz)]2+ to CT-DNA, and found that the
binding constants for interactions of these complexes followed the trend
Ru(II) > Co(III) > Ni(II).145 Another study conducted by Talib and co-workers
found that octahedral nickel(II) complexes containing aromatic ligands
interacted more weakly with DNA than the corresponding ruthenium(II)
complexes, and attributed this to the difference in size of the metal
complexes.144

1.4.2 Metal complexes that bind to quadruplex DNA
Although most of the reported quadruplex DNA stabilisers are purely organic
compounds

with

heteroaromatic

structures,

recent

studies

have

demonstrated that metal complexes can also bind to and stabilise quadruplex
DNA effectively. This includes complexes in which metals are coordinated to
planar

aromatic

ligands

such

as

salphen

(N,N′-

bis(salicylidene)phenylenediamine), terpyridines, and phenanthrolines. A
manganese(III) porphyrin was the first planar metal complex to be
investigated for its potential to act as a qDNA stabilising agent.148 This
complex combined a central aromatic core and four flexible cationic arms
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(Figure 1.16a), and showed a high affinity for the human telomeric
quadruplex DNA (GGGTTA)4. It was able to discriminate between quadruplex
DNA and two different duplex DNA molecules (GC-rich and AT-rich) by a
factor of 1000 in favour of the quadruplex derived from the human telomeric
sequence. In contrast, a related manganese porphyrin analogue Mn-TMPyP
(Figure 1.16b), and the corresponding free base TMPyP, both showed high
affinity for duplex DNA73,149-151 The high affinity and selectivity of the
manganese(III) porphyrin shown in Figure 1.16a toward telomeric qDNA was
found to be due to the combination of the central aromatic core and the four
flexible cationic arms. Additional studies were conducted to investigate the
ability of other metalloporphyrins with manganese(III) or nickel(II) centres to
target quadruplexes formed from telomeric DNA.149,152 These showed that
metalloporphyrins were capable of inhibiting telomerase with IC 50 values in
the micromolar range. In addition, it was found that the nature of the metal
centre and its coordination geometry plays an important role in the kinetics of
binding and nature of the binding modes used in interactions with quadruplex
DNA.
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Figure 1.16: Structure of some metal porphyrin complexes that have been
shown to bind to and stabilise quadruplex DNA: a) a manganese(III)
porphyrin complex, and b) Mn-TMPyP4.

A different class of quadruplex-stabilizing and telomerase-inhibiting metal
complexes was investigated by Reed and co-workers.153 These were square
planar platinum(II) complexes containing substituted phenanthroline ligands
(Figure 1.17). FRET (Fluorescence Resonance Energy Transfer) was used
to study the interactions between these platinum(II) complexes and both
duplex and quadruplex DNA. It was found that the platinum(II) complexes
with the piperidine-containing ligand (Figure 1.17b) induced a high degree of
stabilisation of quadruplex DNA formed from the human telomeric sequence,
which indicated that the piperidine substituent had a significant positive effect
on the interaction between the complex and qDNA.
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Figure 1.17: Structure of some platinum(II) complexes shown to bind to
quadruplex DNA by Reed and co-workers.153

Reed and co-workers have also reported that some nickel(II) salphen
complexes can act as a new type of telomeric quadruplex DNA stabiliser and
telomerase inhibitor.154 Qualitative molecular modelling studies showed that
these

Ni(II)

complexes

(Figure

1.18) possess

the

main

structural

requirements to be quadruplex-stabilizing molecules. These include the πdelocalized system of the salphen ligands, which can stack on a guanine
quartet, the positively charged piperidine substituents, which interact with the
grooves and loops and the negatively charged phosphate backbone of the
quadruplex, and finally the positively charged nickel ion that was found to lie
above the centre of a G-quartet.154 These planar complexes were also found
to induce telomerase inhibition with telEC50 values in the order of ~ 0.1 mM.
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Figure 1.18: Structure of some nickel(II) salphen complexes shown to bind to
quadruplex DNA by Reed and co-workers.154

A later study was conducted to further explore the ability of metal Schiff base
complexes as selective qDNA binders and telomerase inhibitors. This study
investigated the effect of changing the number of aromatic ring systems
present in the complexes shown in Figure 1.18, or the identity of side chains,
on their qDNA binding properties.155 In addition, the effect of changing the
metal ion in the Schiff base complex, and therefore its overall geometry, on
the ability to interact with the G-quadruplex DNA F21T (sequence: 5-FAMd(GGG[TTAGGG]3)-TAMRA-3)

using

a

FRET

melting

assay,

was

explored.155 The structures of some of these complexes are presented in
Figure 1.19. The results of the FRET assay clearly revealed that the square
planar nickel(II) and copper(II) complexes were highly effective stabilizers of
human telomeric DNA. It was found that the change in melting temperature
(ΔTm) induced by nickel salphen complexes which contained different
piperidine and morpholine side chains ranged between 26.4 and 31.6 °C.
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Figure 1.19: Structure of some of the metal Schiff base complexes whose
qDNA-binding properties were studied by Arola-Arnal and co-workers.155

These results suggested that variations in the cyclic amine substituents do
not make significant differences in the binding affinity of these complexes. On
the other hand, the nickel(II) salen complex in Figure 1.19a exhibited a lower
ΔTm than the corresponding salphen complex in Figure 1.18a, which was
attributed to the former complex having one less aromatic ring able to interact
with a G-quartet of the quadruplex DNA molecule. It was also found that
varying the central metal ion in the complex could dramatically affect the
DNA binding properties. For example, despite the similar square planar
coordination environment around the metal ion for the complexes in Figure
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1.18a and Figure 1.19b, the ΔTm value for the copper complex was found to
be significantly lower.155
Furthermore, the above work revealed that the geometry of the metal
complex had an effect on DNA-binding properties. For example, the distorted
square pyramidal zinc and vanadium complexes (Figure 1.19c and d,
respectively) showed negligible or little interaction with quadruplex DNA. This
was demonstrated by their ΔTm values being considerably lower than that of
the analogous square planar nickel and copper complexes. This indicates
that for optimal binding between metal complexes and quadruplex DNA, the
former must have a square planar geometry in which both faces are available
for π-π stacking with a guanine quartet. FRET competition assays showed
that these metal complexes have a high degree of selectivity for quadruplex
DNA as opposed to duplex DNA.
Recently, the nickel Schiff base complexes shown in Figure 1.20 were
synthesized and their interactions with a duplex DNA molecule, as well as
both tetramolecular and unimolecular DNA quadruplexes, were investigated
using several techniques including ESI-MS, DNA melting temperature
measurements, CD spectroscopy, and FRET assays.156 ESI-MS and DNA
melting temperature measurements suggested that the complex in Figure
1.20b exhibits a lower affinity than that in Figure 1.20a towards a dsDNA
molecule. This could be attributed to inability of the former molecules to more
effectively interact with dsDNA via an intercalation binding mode as a result
of

the

two

aromatic

ring

systems

derived

from

meso-1,2-

diphenylethylenediamine. In contrast, the presence of a single aromatic
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system

that

is

coplanar

with

those

which

originated

from

2,4-

dihydroxybenzaldehyde in the complex shown in Figure 1.20a facilitates
insertion into the stack of dsDNA base pairs.

Figure 1.20: Structure of some of the metal Schiff base complexes whose
qDNA-binding properties were studied by Davis and co-workers.156,157

In addition, ESI-MS and CD spectroscopy suggested that the complex in
Figure 1.20b shows significant binding to a tetramolecular DNA quadruplex.
This could be attributed to the presence of additional binding sites in qDNA
such as the terminal G-tetrads found on the ends of the nucleic acid
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molecules, which allow for π-π stacking interactions between these nickel
complexes and the guanine residues of the G-tetrads. Interestingly, the
results of ESI-MS and FRET assays indicated that the nickel complex in
Figure 1.20b did not bind as tightly to a unimolecular DNA quadruplex. These
results indicate that the presence of the meso-1,2-diphenylethylenediamine
moiety in metal complexes of this type may enhance their selectivity for some
DNA quadruplexes over dsDNA.
The size and position of the aromatic surface area within the nickel Schiff
base complexes was found to be important for DNA binding interactions. For
example, it was found that the complex in Figure 1.20c exhibited a high
affinity for dsDNA, but a limited binding to qDNA molecules. 157 This could be
attributed to the presence of a large planar 9,10-diaminophenanthrene unit
which facilitates insertion into the stack of dsDNA base pairs, but sterically
hinders the approach of the nickel Schiff base molecules to the loops of the
qDNA molecule. In addition, ESI-MS, CD spectroscopy and UV-Vis DNA
melting studies suggested that the asymmetric complex shown in Figure
1.20d which contained a single naphthaldehyde moiety, exhibited a
significant decrease in its ability to bind to dsDNA, as well as a limited
binding to qDNA.157

This result could be attributed to the lack of the

electrostatic interactions due to the presence of only one piperidine group
that can be protonated in the solution, as well as the presence of the
naphthaldehyde unit which may hinder the approach of the nickel Schiff base
molecules to the dsDNA and to G-quadruplexes. Furthermore, the effect of
changing the length or chemical composition of side chains present in the
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complexes shown in Figure 1.20, upon their DNA binding properties was also
explored.157 Both ESI-MS and CD spectroscopy studies revealed that the
replacement of the alkyl chains by either propyl piperidine or ethyl morpholine
did not result in any significant enhancements in DNA affinity or selectivity.

1.5 Aims
The results of studies described in the previous section indicate that
changing the structure of nickel Schiff base complexes can enhance their
binding affinity and selectivity for qDNA. These changes included increasing
the number of aromatic moieties present in their structure, and the length and
chemical composition of the pendant groups. However, to date, the effect of
varying the position of the pendant groups on the ability of those complexes
to bind to qDNA and their selectivity for qDNA over dsDNA, has not been
explored.
Therefore, the aims of this project were to:
1. Synthesize the hydroxylated nickel Schiff base complexes shown in
Figure 1.21.
2. Synthesize the alkylated nickel Schiff base complexes (7) – (12)
shown in Figure 1.22 by reacting the complexes in Figure 1.21 with 1(2-chloroethyl)piperidine hydrochloride. These complexes are isomers
of those shown in Figure 1.18a, Figure 1.19a, and Figure 1.20a. The
source

of

isomers

stems

from

the

identity

of

the

dihydroxybenzaldehyde (2,3- or 2,5- isomer, as opposed to 2,436

isomer) used during the first stage of synthetic procedure used to
prepare the metal complex.

Figure 1.21: Structures of the hydroxylated nickel Schiff base complexes
synthesized in this study.

3. Characterize the above complexes by mass spectrometry, as well as
NMR spectroscopy, microanalysis and, where possible, X-ray
crystallography.
4. Use electrospray ionization mass spectrometry and circular dichroism
spectroscopy to compare the interactions between the nickel Schiff
base complexes shown in Figure 1.22 with a duplex DNA molecule
(D2) and a tetramolecular quadruplex DNA (Q4), with that of the
isomeric complexes previously reported.
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Figure 1.22: Structures of the alkylated nickel Schiff base complexes under
study.
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CHAPTER 2
MATERIALS AND METHODS

2.1 Chemicals
All solvents and reagents used in this study were of the highest grade
commercially available. Milli-QTM water (Millipore, Molsheim, France) was
used in all experiments. Nickel compounds (13), (14) and (15) were obtained
from PhD student Kimberley Davis (School of Chemistry, University of
Wollongong,

Australia).

1-(2-Chloroethyl)piperidine

hydrochloride,

2,3-

dihydroxybenzaldehyde, 2,5-dihydroxybenzaldehyde, magnesium sulfate
(MgSO4),

1,2-phenylenediamine,

diphenylethylenediamine,

nickel

1,2-ethylenediamine,

acetate

tetrahydrate

1,2-meso-

(Ni(OAc)2·4H2O),

DMSO-d6 ((CD3)2SO), CDCl3 and cesium iodide (Fluka brand) were all
purchased from Sigma-Aldrich (Castle Hill, Australia). Potassium carbonate
(K2CO3), dimethylformamide (DMF), dichloromethane (DCM), dimethyl
sulfoxide (DMSO), acetic acid (CH3COOH), methanol (MeOH), anhydrous
diethyl ether (Et2O), aluminium oxide used in column chromatography, as
well as acetonitrile (ACN), ammonia and ammonium acetate (NH4OAc) that
were used in HPLC purification of oligonucleotides and ESI-MS experiments,
were all purchased from Ajax Finechem (Seven Hills, Australia). All
oligonucleotides were obtained either from Geneworks (Adelaide, South
Australia) or Sigma-Aldrich (Castle Hill, Australia).
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2.2 Characterisation of nickel Schiff base complexes
2.2.1 Physical measurements

Elemental microanalysis determination for the elements carbon, hydrogen,
nitrogen and nickel were performed at the Campbell Microanalytical
Laboratory at the Chemistry Department of the University of Otago, New
Zealand. NMR spectra of the nickel complexes dissolved either in DMSO-d6
or CDCl3 were obtained using a Varian Inova-500 MHz NMR spectrometer at
25 °C. The chemical shifts of the resonances observed in 1H and

13C

NMR

spectra were reported in ppm (δ) relative to either tetramethylsilane (TMS) or
the solvent peak as an internal standard. In 1H NMR spectra, the signal from
the small amount of CHCl3 present in CDCl3 solvent was reported at 7.26
ppm, while the signal from the small amount of CD3SOCD2H present in
DMSO-d6 solvent was reported at 2.50 ppm. For

13C

NMR spectra, the

resonance from the CDCl3 solvent was set to 77.7 ppm, while that from
DMSO-d6 solvent was assigned to 39.6 ppm. Hydrogen and carbon
resonances were fully assigned through the use of 2D experiments including
Correlation Spectroscopy (COSY), Nuclear Overhauser Effect Spectroscopy
(NOESY),

Heteronuclear

Single-Quantum

Correlation

(HSQC)

and

Heteronuclear Multiple-Bond Correlation (HMBC) spectroscopy. Electrospray
ionisation (ESI) mass spectra of alkylated nickel Schiff base complexes were
obtained using a Waters Quattro ESI mass spectrometer (Milford,
Massachusetts, USA), using solutions prepared in H2O:MeOH (50:50).
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2.2.2 Crystallography

X-ray structural studies were performed by Dr Anthony C. Willis at the
Research School of Chemistry, the Australian National University, Canberra,
Australia. The X-ray diffraction measurements performed on complexes (5),
(8) and (10) were carried out at 150 K on an Xcalibur diffractometer with
Atlas detector using Mo Kα radiation, λ = 0.71073 Å. Data reduction and cell
refinement were accomplished using CrysAlis PRO software.158 The
structures were solved with SIR92, and refined using the program
CRYSTALS.159,160 Molecular graphics were produced using PLATON.161
During refinement of (5) hydrogen atoms bonded to C were positioned
geometrically and the water H atoms were based on peaks from a difference
electron density map and potential H-bonded contacts. The H atoms were
initially refined with soft restraints on the bond lengths and angles to
regularize their geometry (C-H in the range 0.93-0.98 Å, O-H = 0.82 Å) and
with Uiso(H) in the range 1.2-1.5 times Ueq of the parent atom, after which the
positions were refined with riding constraints.
During refinement of (8), the H atoms were all located in a difference map,
but those bonded to C were repositioned geometrically. The H atoms were
initially refined with soft restraints on the bond lengths and angles to
regularize their geometry (C-H in the range 0.93-0.98 Å, O-H = 0.83 Å) and
with Uiso(H) in the range 1.2-1.5 times Ueq of the parent atom, after which the
positions were refined with riding constraints except for those bonded to O
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which were allowed to refine freely. The largest features in the final difference
electron density map are located midway between bonded atoms.
During refinement of (10) the program PLATON was used to identify a
twinning relationship in the data. Application of a twinning correlation within
CRYSTALS to allow for overlapping reflections, based on the above
relationship, gave a small improvement in the agreement factors. The final
refined values for the twin elements were 0.704(5) and 0.296(5). Hydrogen
atoms bonded to C were positioned geometrically and the water H atoms
were based on peaks from a difference electron density map and potential Hbonded contacts. The H atoms were initially refined with soft restraints on the
bond lengths and angles to regularize their geometry (C-H in the range 0.930.98 Å, O-H = 0.82 Å) and with Uiso(H) in the range 1.2-1.5 times Ueq of the
parent atom, after which the positions were refined with riding constraints.

2.3 Oligonucleotides
2.3.1 Purification of single-stranded oligonucleotides

Single-stranded oligonucleotides (D2A, D2B and q4) were purchased from
either Sigma-Aldrich (Castle Hill, Australia), or Geneworks (South Australia),
as freeze-dried ‘trityl-off’ derivatives. The base sequences of DNA molecules
which were used in this study are presented in Table 2.1. These
oligonucleotides were purified using high performance liquid chromatography
(HPLC) by following previously reported procedures.157,162,163 Purified DNA
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solutions were then freeze-dried using a Savant speedVac (Selby-Biolab,
Australia) prior to storage at -20 °C.
When required, freeze-dried samples were dissolved in 1000 μL of Milli-QTM
water. Diluted solutions (300× dilution factor) were prepared by adding 2 μL
of one of the above DNA solutions to 598 μL of Milli-QTM water. In order to
determine the concentration of the final DNA solutions, the absorbance at
260 nm was measured, and the molar absorbtion coefficients (ε) of the
individual nitrogenous bases present in the DNA sequence were used to
obtain an overall value of ε for the oligonucleotide itself. Values of ε for the
purine

and

pyrimidine

bases

were

obtained

from

the

website,

Oligonucleotides Properties Calculator.164

Table 2.1: Properties of the DNA molecules used in this study.
Oligonucleotide sequence
GCTGCCAAATACCTCC

DNA
label
D2A

Mass
(Da)
4786.2

GGAGGTATTTGGCAGC
(GCTGCCAAATACCTCC/GGAGGTATTTGGCAGC)
TTGGGGGT
(TTGGGGGT)4

D2B
D2
q4
Q4

4977.3
9763.5
2496.7
9986.6

2.3.2 Preparation of dsDNA (D2)

Appropriate quantities of single-stranded DNA (ssDNA) solutions (D2A and
D2B) were mixed together in an Eppendorf tube and dried using the Savant
SpeedVac before being dissolved in an appropriate volume of NH4OAc
solution (100 mM, pH 7.4) to give a final dsDNA concentration of 1 mM. The
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DNA was then annealed by heating the resulting DNA solution in a water
bath at 61 °C (the melting temperature of the DNA plus 15 °C)164 for 15 min,
after which it was allowed to cool slowly to room temperature overnight.

2.3.3 Preparation of qDNA (Q4)

An appropriate quantity of solution containing the ssDNA q4 was placed in an
Eppendorf tube, dried and then redissolved in sufficient NH4OAc solution
(150 mM, pH 7.4) to give a final concentration of 1 mM. The DNA was then
annealed by heating the resulting solution in a water bath at 90 °C for 15 min,
after which it was allowed to cool slowly to room temperature overnight.

2.4 Reactions of oligonucleotides with nickel Schiff
base complexes
2.4.1 ESI-MS experiments

Stock solutions of nickel complexes (1 mM) were prepared in a mixture of
acetic acid:MeOH (1:99) for all DNA-binding studies. Reaction mixtures
containing different ratios of DNA (10 μM) and nickel complex were prepared
in NH4OAc solution (100 and 150 mM for D2 and Q4, respectively). This
gave mixtures with final DNA:metal complex ratios of 1:1, 1:3, 1:6 and 1:9.
The volumes of different reagent solutions used to prepare these reaction
mixtures are presented in Table 2.2.
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Table 2.2: Volume of stock solutions used to prepare nickel/DNA samples for
analysis by ESI-MS.
DNA:metal
complex ratio

Volume of DNA
(1 mM stock)
(μL)

1:1
1:3
1:6
1:9

1
1
1
1

Volume of
metal complex
(1 mM stock)
(μL)
1
3
6
9

Volume of
buffer
(μL)
98
96
93
90

ESI-MS was used to investigate the binding of nickel complexes to dsDNA
and qDNA. A Waters Q-ToF UltimaTM ESI mass spectrometer (Manchester,
UK) was used to acquire mass spectra in negative ion mode. The instrument
was calibrated using a cesium iodide (CsI) solution (1 mg/mL), prior to
acquiring the spectra of samples containing DNA and nickel complexes. The
samples were injected into the mass spectrometer using a Harvard model 22
syringe pump (Natick, USA) at a constant flow rate (10 μL/min). The
parameters used to obtain the spectra for all experiments are listed in Table
2.3.

Table 2.3: ESI-MS conditions used for the analysis of DNA/metal complex
solutions.
MS parameter
Capillary (kV)
Cone (V)
Source temperature (°C)
Desolvation temperature (°C)
Desolvation gas flow (L/Hr)

Setting
2.50
60
25
80
100
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2.4.2 CD Experiments

A Jasco J-810 spectropolarimeter and 0.1 cm path length quartz cell was
used to obtain CD spectra between 200 and 400 nm. The instrument
parameters used to acquire these spectra are listed in Table 2.4.
Table 2.4: Instrument parameters used to acquire all CD spectra of nickel/
DNA samples.
CD parameter
Sensitivity
Scanning speed
Response
Band width
Number of accumulations
Temperature

Setting
standard
100 nm/min
4s
1 nm
6
25 °C

The CD spectra were obtained first for a 300 μL solution containing either D2
or Q4 (20 μM) dissolved in NH4OAc solution of the appropriate concentration.
Aliquots of a stock solution (Table 2.5) containing both the same type of DNA
(20 μM) and nickel complex (0.6 mM), were then added to the initial DNA
solution in order to produce samples with DNA:metal complex ratios of 1:1,
1:3, 1:6 and 1:9. CD spectra were obtained after each new solution was
made.
Table 2.5: Volumes of the DNA/metal complex stock required for CD
samples.
DNA: metal complex ratio
1:1
1:3
1:6
1:9

Volume of DNA/nickel complex stock
solution added (μL)
10.4
23.0
41.7
53.6
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CHAPTER 3
SYNTHESIS AND CHARACTERISATION
OF NICKEL SCHIFF BASE COMPLEXES.

3.1 Synthesis of hydroxylated nickel Schiff base
complexes
N, N′-Bis-5-(hydroxysalicylidine)ethylenediaminenickel(II) (1)

This compound was prepared by following a previously reported method. 155
2,5-Dihydroxybenzaldehyde (676 mg, 4.89 mmol) and 1,2-ethylenediamine
(197 mg, 3.30 mmol) were dissolved in MeOH (50 mL), forming a transparent
light orange solution. The mixture was heated with constant stirring under
reflux for 30 min, after which Ni(OAc)2·4H2O (1.24 g, 4.96 mmol) was added,
forming a chocolate brown coloured precipitate. Refluxing was continued for
another 3 h. After this time, the solution was allowed to cool to room
temperature. The red-brown solid present was collected by vacuum filtration,
and then washed with MeOH (100 mL), diethyl ether (50 mL) and water (50
mL). The compound was then dried under vacuum for a further 1 h. Yield:
0.81 g, 92.0 %. Microanalysis calc. for C16H14N2NiO4·4H2O: C = 44.80; H =
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5.17; N = 6.53; Ni = 13.68 %. Found: C = 44.83; H = 4.25; N = 6.53; Ni =
14.00 %. 1H NMR (500 MHz, DMSO-d6): δ 3.36 (s, 4H, H1); 6.55 (d, 2H, J =
8.74 Hz, H7); 6.58 (d, 2H, J = 2.38 Hz, H4); 6.73 (dd, 2H, J = 2.39 and 8.74
Hz, H6); 7.77 (s, 2H, H2); 8.55 (s, 2H, OH); 13C NMR (125 MHz, DMSO-d6): δ
58.36 (C1); 115.09 (C4); 119.57 (C3); 120.47 (C7); 124.43 (C6); 146.18 (C5);
158.72 (C8); 162.42 (C2);
N, N′-Bis-5-(hydroxysalicylidine)phenylenediaminenickel(II) (2)

This compound was prepared by following a previously reported method.154
2,3-Dihydroxybenzaldehyde (695 mg, 5.03 mmol) and 1,2-phenylenediamine
(239 mg, 2.21 mmol)

were dissolved in MeOH (50 mL), forming a

transparent light yellow solution. This was heated under reflux with constant
stirring for 30 min, during which time the solution changed to a dark orange
colour. Ni(OAc)2·4H2O (1.27 g, 5.09 mmol) was subsequently added, and a
dark red-brown precipitate formed immediately. The reaction mixture was
heated under reflux for a further 3 h, after which the solution was allowed to
cool to room temperature. The precipitate that remained was collected by
vacuum filtration and then washed sequentially with MeOH (100 mL), diethyl
ether (50 mL) and water (50 mL). The compound was then dried under
vacuum for 2 h. Yield: 1.00 g, 98.0 %. Microanalysis calc. for
C20H14N2NiO4·1.25H2O: C =56.19; H =3.89; N = 6.55 %. Found: C =56.14; H
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= 3.68; N = 6.49 %. 1H NMR (500 MHz, DMSO-d6): δ 6.76 (d, 2H, J = 8.7 Hz,
H9); 6.90 (s, 2H, H6); 6.92 (broad s, 2H, H8); 7.29 (m, 2H, H1); 8.13 (m, 2H,
H2); 8.80 (s, 2H, H4); 8.82 (s, 2H, OH).

13C

NMR (125 MHz, DMSO-d6):

115.15 (C6); 116.44 (C2); 119.51 (C5); 121.07 (C9); 127.25 (C8); 127.57
(C1); 142.81 (C3); 146.78 (C7); 155.71 (C4); 160.80 (C10).
N, N′-Bis-5-(hydroxysalicylidine)meso-diphenylethylenediaminenickel(II) (3)

2,5-Dihydroxybenzaldehyde

(675

mg,

4.89

mmol)

and

1,2-meso-

diphenylethylenediamine (537 mg, 2.53 mmol) were dissolved in MeOH (50
mL), forming a transparent light yellow solution. This was heated under reflux
with constant stirring for 30 min. During this time the solution changed to an
orange colour. Ni(OAc)2·4H2O (1.24 g, 4.96 mmol) was subsequently added,
and a dark green precipitate formed immediately. This solution was heated
under reflux for a further 3 h. After the solution was allowed to cool to room
temperature, the precipitate was isolated by vacuum filtration and dried. The
green solid was then washed with MeOH (100 mL), diethyl ether (50 mL) and
water (50 mL), before being dried under vacuum for a further 1 h. Yield: 0.98
g, 79.0 %. Microanalysis calc. for C28H22N2NiO4·2H2O: C = 61.69; H = 4.81;
N = 5.14; Ni = 10.77 %. Found: C = 61.72; H = 4.57; N = 5.14; Ni = 11.00 %.
1H

NMR (500 MHz, DMSO-d6): δ 5.02 (s, 2H, H7); 6.40 (d, 2H, J = 2.6 Hz,

H10); 6.62 (d, 2H, J = 9.1 Hz, H13); 6.78 (dd, 2H, J = 2.7, 9.00 Hz, H12);
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7.27 (m, 6H, H2, 3 and 4); 7.40 (broad s, 4H, H1 and 5); 7.45 (s, 2H, H8);
8.52 (s, 2H, OH);

13C

NMR (125 MHz, DMSO-d6): δ 76.40 (C7); 115.06

(C10); 119.44 (C9); 120.63 (C13); 125.23 (C12); 128.70 (C3); 128.83 (4C,
C2 and C4); 129.60 (4C, C1 and C5); 136.38 (C6); 146.40 (C11); 159.07
(C14); 162.34 (C8).
N, N′-Bis-3-(hydroxysalicylidine)ethylenediaminenickel(II) (4)

This compound was prepared by following a previously reported method. 155
2,3-Dihydroxybenzaldehyde (676 mg, 4.89 mmol) and 1,2-ethylenediamine
(197 mg, 3.27 mmol) were dissolved in MeOH (50 mL), forming a light yellow
suspension. This stirred reaction mixture was heated under reflux for 30 min,
during

which

time

the

solution

Ni(OAc)2·4H2O (1.24 g, 4.96 mmol)

colour

changed

to

dark

orange.

was then added, and a dark green

precipitate formed immediately. This mixture was heated under reflux for a
further 3 h. After the reaction was completed, the mixture was allowed to cool
to room temperature, and the green solid isolated by vacuum filtration and
dried. It was then washed with MeOH (100 mL), diethyl ether (50 mL) and
water (50 mL), before being dried under vacuum for a further 2 h. Yield: 0.70
g, 80.0 %. Microanalysis calc. for C16H14N2NiO4·H2O: C = 51.25; H = 4.30; N
= 7.47; Ni = 15.65 %. Found: C = 51.09; H = 3.94; N = 7.43; Ni = 15.60 %.1H
NMR (500 MHz, DMSO-d6): δ 3.43 (s, 4H, H1); 6.38 (t, 2H, J = 7.68 Hz, H5);
6.69 (dd, 2H, J = 1.54 and 7.49 Hz, H6); 6.74 (dd, 2H, J =1.53 and 8.06 Hz,
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H4); 7.88 (s, 2H, C2); 8.16 (broad s, OH).

13C

NMR (125 MHz, DMSO-d6): δ

58.45 (C1); 114.81 (C5); 114.95 (C6); 119.61 (C3); 122.40 (C4); 148.15 (C7);
153.13 (C8); 163.21 (C2).
N, N′-Bis-3-(hydroxysalicylidine)phenylenediaminenickel(II) (5)

2,3-Dihydroxybenzaldehyde

(695

mg,

5.03

mmmol)

and

1,2-

phenylenediamine (284 mg, 2.63 mmol) were dissolved in MeOH (50 mL),
forming a transparent dark yellow solution. This was heated for 30 min at
reflux with constant stirring, during which time the solution colour changed to
dark orange. Ni(OAc)2·4H2O (1.27 g, 5.10 mmol) was then added to the
mixture, and immediately resulted in a deep red-brown precipitate. This
solution continued to be heated under reflux for 3 h, after which it was
allowed to cool to room temperature. The precipitate that had formed was
separated by vacuum filtration and dried. It was subsequently washed with
MeOH (100 mL), diethyl ether (50 mL) and water (50 mL), before being dried
under vacuum for a further 2 h. Yield: 0.69 g, 68.0 %. The product was
purified by crystallization from a MeOH-DMSO (70:30) mixture. Microanalysis
calc. for C20H14N2NiO4·2H2O: C = 54.47; H = 4.11; N = 6.35; Ni = 13.31%.
Found: C = 54.57; H = 3.48; N = 6.22; Ni = 13.20 %.1H NMR (500 MHz,
DMSO-d6): δ 6.54 (t, 2H, J = 7.63 Hz, H7); 6.81 (d, 2H, J = 6.67 Hz, H8); 7.09
(d, 2H, J = 8.10 Hz, H6); 7.35 (m, 2H, H1); 8.17 (m, 2H, H2); 8.51 (s, 2H,
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H4); 9.12 (s, 2H, OH).

13C

NMR (125 MHz, DMSO-d6): δ 115.84 (C7); 116.13

(C8); 116.83 (C2); 119.70 (C5); 123.88 (C6); 128.12 (C1); 142.66 (C3);
148.66 (C9); 154.99 (C10); 157.21 (C4).
N, N′-Bis-3-(hydroxysalicylidine) meso-diphenylethylenediaminenickel(II) (6)

2,3-Dihydroxybenzaldehyde

(676

mg,

4.89

mmol)

and

1,2-meso-

diphenylethylenediamine (537 mg, 2.53 mmol) were dissolved in MeOH (50
mL), forming a transparent light yellow solution. The mixture was heated with
constant stirring under reflux for 30 min. During this time the solution
changed colour to dark orange. Ni(OAc)2·4H2O (1.23 g, 4.96 mmol) was
added to the reaction mixture, and a dark green precipitate formed
immediately. Heating under reflux was continued for another 3 h, after which
the solution was allowed to cool to room temperature, and the resulting
precipitate was isolated by vacuum filtration. The solid was then washed with
MeOH (100 mL), diethyl ether (50 mL) and water (50 mL), before being dried
under vacuum for a further 2 h. Yield: 1.20 g, 97.0 %. Microanalysis calc. for
C28H22N2NiO4·1.5H2O: C = 62.72; H = 4.70; N = 5.22 %. Found: C = 62.68;
H = 4.41; N = 5.19 %. 1H NMR (500 MHz, DMSO-d6): δ 5.08 (broad, s, 2H,
H7); 6.34 (t, 2H, J = 8.03 Hz, H11); 6.61 (d, 2H, J = 6.76 Hz, H10); 6.70 (d,
2H, J = 5.91 Hz, H12); 7.26-7.28 (m, 6H, H2, H3 and H4); 7.42 (br, s, (4H,
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H1 and H5 ); 7.57 (s, 2H, C8); 8.34 (s, 2H, OH).

13C

NMR (125 MHz, DMSO-

d6): δ 76.72 (C7); 115.33 (C11); 115.71 (C12); 119.74 (C9); 122.97 (C10);
128.98 (C3); 129.13 (C2 and C4); 129.83 (C1 and C5); 136.35 (C6); 148.37
(C13); 153.73 (C14); 163.45 (C8).

3.2 Synthesis of alkylated nickel Schiff base
complexes
N,N′-Bis[5-[[1-(2-ethyl)piperidine]oxy]salicylidine]ethylenediaminenickel(II) (7)

A suspension of compound (1) (107 mg, 0.30 mmol), 1-(2-chloroethyl)
piperidine hydrochloride (216 mg, 1.17 mmol) and K 2CO3 (284 mg, 2.05
mmol) was made in anhydrous DMF (10 mL) and stirred for 72 h under N2.
During this time a green precipitate appeared in the bright brown solution.
After the end of the reaction, the DMF was removed from the mixture under
low pressure to yield a dark green solid. This was then dissolved in DCM (30
mL), and insoluble material removed by gravity filtration. The filtrate was then
washed with water seven times, and then dried using MgSO4, before the
DCM was allowed to evaporate. The desired compound was subsequently
obtained as a dark green solid. Yield 0.11 g, 63.0 %. ESI-MS calc.
53

[C30H40N4O4Ni+H]+

=

579.4,

[C30H40N4O4Ni+2H]2+

=

289.7.

Found:

[C30H40N4O4Ni+H]+ = 579.1, [(C30H40N4O4Ni + 2H)]2+= 290.2. Microanalysis
calc. for C30H40N4NiO4: C = 62.20; H = 6.96; N = 9.67 %. Found: C = 62.18;
H = 6.98; N = 9.53 %.1H NMR (500 MHz, CDCl3): δ 1.45 (m, 4H, H13); 1.60
(m, 8H, H12); 2.48 (broad s, 8H, H11); 2.71 (t, 4H, J = 6.04 Hz, H10); 3.41 (s,
4H, H1); 3.97 (t, 2H, J = 6.04 Hz, H9); 6.46 (d, 2H, J = 2.66 Hz, H4); 6.90
(dd, 2H, J = 2.66 and 9.29 Hz, H6); 6.94 (d, 2H, J = 9.18 Hz, H7); 7.35 (s,
2H, H2).

13C

NMR (125 MHz CDCl3): δ 24.18 (C13); 25.90 (C12); 55.05

(C11); 58.07 (C10); 58.44 (C1); 66.70 (C9); 112.99 (C4); 118.47 (C3); 122.57
(C7); 124.92 (C6); 148.39 (C5); 160.52 (C8); 161.20 (C2).
N,N′-Bis[5-[[1-(2-ethyl)piperidine]oxy]salicylidine]phenylendiaminenickel(II)
(8)

This compound was prepared by following a previously reported method. 154
Compound (2) (122 mg, 0.30 mmol) was suspended in anhydrous DMF (10
mL), along with 1-(2-chloroethyl)piperidine hydrochloride (215.7 mg, 1.17
mmol) and K2CO3 (284 mg, 2.05 mmol) and stirred for 72 h under N2. During
this time a brown precipitate appeared, and the K2CO3 disappeared. After the
end of the reaction time, the DMF was removed from the mixture under low
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pressure to yield a red-brown solid. This was then dissolved in DCM (30 mL)
and washed with water five times, and then dried using MgSO4, before the
DCM was allowed to evaporate under low pressure to yield a dark red-brown
crystalline product. Yield: 0.10 g, 53.0 %. ESI-MS calc: [C34H40N4O4Ni+H]+ =
628.4, [C34H40N4O4Ni+2H]2+ = 314.7. Found: [C34H40N4O4Ni+H]+ = 627.2,
[C34H40N4O4Ni +2H]2+ = 314.2. Microanalysis calc. for C34H40N4NiO4·2H2O: C
= 61.56; H = 6.68; N = 8.44; Ni = 8.85 %. Found: C = 61.37; H = 6.52; N =
8.13; Ni = 8.70 %. 1H NMR (500 MHz, CDCl3): δ 1.47 (m, 4H, H15); 1.63 (t,
8H, J = 5.57 Hz, H14); 2.51 (broad s, 8H, H13); 2.75 (t, 4H, J = 6.16 Hz,
H12); 4.04 (t, 4H, J = 6.16 Hz, H11); 6.68 (d, 2H, J = 2.64 Hz, H6); 7.02 (dd,
2H, J = 2.93 and 9.38 Hz, H8); 7.09 (d, 2H, J = 9.38 Hz, H9); 7.18-7.20 (m,
2H, J = 2.93, H1); 7.69-7.71 (m, 2H, J = 3.51 Hz, H2); 8.16 (s, 2H, H4).

13C

NMR (125 MHz, CDCl3): δ 24.35 (C15); 26.09 (C14); 55.23 (C13); 58.19
(C12); 66.85 (C11); 112.43 (C6); 114.85 (C2); 118.56 (C5); 123.33 (C9);
127.29 (C1); 127.59 (C8); 142.89 (C3); 149.18 (C7); 153.28 (C4); 162.80
(C10).
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N,N′-Bis[5-[[1-(2-ethyl)piperidine]oxy]salicylidine]meso-diphenylethylenediaminenickel(II) (9)

The

synthesis

of

this

complex

was

monitored

using

thin

layer

chromatography (TLC). A suspension of compound (3) (166 mg, 0.3 mmol),
1-(2-chloroethyl) piperidine hydrochloride (222 mg, 1.2 mmol) and K 2CO3
(294 mg, 2.1 mmol) in anhydrous DMF (10 mL) was stirred for 6 d under N2.
TLC analysis showed that after this time the starting material was still present
in the reaction mixture. Therefore, the reaction was heated to 50 °C for a
further 48 h under N2 at 50 °C. The reaction was stopped after 48 h when
TLC showed that no starting material remained in the mixture. After this time,
the precipitate present was removed by gravity filtration. The DMF was then
evaporated under low pressure to yield a red solid, which was then dissolved
in DCM (30 mL), and washed with water seven times. All precipitates which
appeared during the washing process were removed by gravity filtration.
After the washing step, the DCM solution was dried with MgSO4, and
evaporated yielding 0.05 g of a red solid. An ESI mass spectrum of the
resulting solid dissolved in MeOH:H2O (50:50)) did not show any ions which
could be assigned to complex (9). In addition, the 1H NMR spectrum of the
product contained many broad and overlapping signals, indicating that it was
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likely to be a mixture of compounds. In other attempts to synthesise complex
(9), the same procedure as above was followed but different concentrations
of either the hydroxylated precursor complex or 1-(2-chloroethyl) piperidine
hydrochloride were used. Again ESI mass spectra and 1H NMR spectra did
not show any sign of complex (9) in the products obtained. After these failed
attempts to synthesise complex (9), it was decided to remove this compound
from the list of target molecules to be used in DNA-binding studies.

N,N′-Bis[3-[[1-(2-ethyl)piperidine]oxy]salicylidine]ethylenediaminenickel(II)
(10)

A suspension of compound (4) (107 mg, 0.30 mmol), 1-(2-chloroethyl)
piperidine hydrochloride (216 mg, 1.17 mmol) and K 2CO3 (283 mg, 2.05
mmol) was made in anhydrous DMF (10 mL) and stirred for 72 h under N2.
During this time, a dark yellow precipitate appeared, and the K 2CO3
disappeared. Upon completion of the reaction, the DMF was removed under
low pressure to yield a red solid, which was dissolved in DCM (30 mL). After
removal of some insoluble materials by gravity filtration, the filtrate was
washed with water five times, dried with MgSO4 and the DCM evaporated, to
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yield a brown solid. Yield: 90.0 mg, 53.0 %. ESI-MS calc: [C30H40N4O4Ni+H]+
= 579.4, [C30H40N4O4Ni+2H]2+ = 289.7. Found: [C30H40N4O4Ni+H]+ = 579.1,
[C30H40N4O4Ni + 2H]2+ = 290.2. Microanalysis calc. for C30H40N4NiO4·2H2O:
C = 58.56; H = 7.21; N = 9.10; Ni = 9.54 %. Found: C = 58.31; H = 7.04; N =
8.96; Ni = 9.40 %. 1H NMR (500 MHz, CDCl3): δ 1.45 (broad s, 4H, H13);
1.64 (m, 8H, H12); 2.56 (broad s, 8H, H11); 2.93 (t, 4H, H10); 3.40 (s, 4H,
H1); 4.13 (t, 4H, H9); 6.45 (t, 2H, J = 7.40 Hz, H5); 6.72 (d, 2H, J = 7.40 Hz,
H4); 6.76 (d, 2H, J = 6.87 Hz, H6); 7.49 (s, 2H, H2).

13C

NMR (125 MHz,

CDCl3): δ 24.31 (C13); 25.96 (C12); 55.27 (C11); 57.61 (C10); 58.54 (C1);
66.11 (C9); 113.96 (C5); 114.56 (C6); 120.18 (C3); 124.14 (C4); 149.95 (C7);
155.83 (C8); 161.66 (C2).
N,N′-Bis[3-[[1-(2-ethyl)piperidine]oxy]salicylidine]phenylenediaminenickel(II)
(11)

A

suspension

of

compound

(5)

(122

mg,

0.3

mmol),

1-(2-

chloroethyl)piperidine hydrochloride (216 mg, 1.17 mmol) and K 2CO3 (284
mg, 2.05 mmol) in anhydrous DMF (10 mL) was stirred for 96 h under N2.
After this time, the DMF was removed from the reaction mixture under low
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pressure to yield a red solid. This was subsequently added to DCM (30 mL),
and the insoluble portion was removed by gravity filtration. The filtrate was
then washed with water five times, and dried with MgSO 4, before the DCM
was removed under low pressure to afford the product as a dark red solid.
Yield:

0.05

g,

26.0

%.

ESI-MS

[C34H40N44O4Ni+2H]2+ = 314.7.

cal:

[C34H40N4O4Ni+H]+

=

628.4,

Found: (C34H40N4O4Ni+H)]+ = 627.2,

[C34H40N4O4Ni+2H]2+ = 314.3. Microanalysis calc. for C34H40N4NiO4·H2O: C =
61.56; H = 6.68; N = 8.44 %. Found: C = 61.62; H = 6.38; N = 8.37 %. 1H
NMR (500 MHz, CDCl3): δ 1.46 (m, 4H, H15); 1.61 (m, 8H, H14); 2.56 (s, 8H,
H13); 2.96 (t, 2H, J = 6.72, H12); 4.14 (t, 2H, J = 6.72 Hz, H11); 6.56 (t, 2H, J
= 7.68 Hz, H7); 6.79 (d, 2H, J = 7.36 Hz, H8); 6.95 (d, 2H, J = 7.68 Hz, H6);
7.21-7.22 (m, 2H, H1); 7.69-7.70 (m, 2H, H2); 8.24 (s, 2H, H4);

13C

NMR

(125 MHz, CDCl3): δ 24.30 (C15); 25.96 (C14); 55.29 (C13); 57.60 (C12);
66.08 (C11); 114.82 (C2); 115.19 (C7); 115.3 (C8); 119.85 (C5); 124.64 (C6);
127.29 (C1); 142.85 (C3); 150.42 (C9); 154.13 (C4); 157.53 (C10).
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N,N′-Bis[3-[[1-(2-ethyl)piperidine]oxy]salicylidine]meso-diphenylethylenediaminenickel(II) (12)

A

suspension

of

compound

(6)

(165

mg,

0.3

mmol),

1-(2-

chloroethyl)piperidine hydrochloride (221 mg, 1.2 mmol), and K2CO3 (292
mg, 2.1 mmol) in anhydrous DMF (25 mL) was stirred for 72 h under N2. The
reaction was monitored by TLC. After the end of this period, the DMF was
removed from the reaction mixture under low pressure to yield a dark brown
slurry. This was then dissolved in DCM (30 mL), and the resulting solution
filtered under gravity to eliminate excess insoluble starting materials. The
filtrate was then washed with water seven times, and dried with MgSO4,
before the DCM was evaporated to afford the desired product as a yellowish
brown solid. This product was purified by using column chromatography on
alumina, using DCM/methanol (95/5, v/v) as the eluent, to yield the desired
compound (0.11 g, 46.0 %). ESI-MS cal: [C42H48N4O4Ni+H]+ = 731.6,
[C42H48N4O4Ni+2H]2+

=

365.8.

Found:

[C42H48N4O4Ni+H]+

=

731.4,

[(C42H48N4O4Ni + 2H)]2+ = 366.3. Microanalysis calc. for C42H48N4NiO4·H2O:
C = 67.30; H = 6.72; N = 7.47 %. Found: C = 67.40; H = 6.67; N = 7.54 %. 1H
NMR (500 MHz, CDCl3): δ 1.45-1.46 (m, 4H, H19); 1.63 (m, 8H, H18); 2.56
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(m, 8H, H17); 2.96 (t, 4H, J = 6.61 Hz, H16); 4.14 (t, 4H, J = 6.60 Hz, H15);
4.77 (s, 2H, H7); 6.38 (t, 2H, J = 7.73 Hz, H11); 6.52 (d, 2H, J = 7.89 Hz,
H10); 6.74 (d, 2H, J = 7.61 Hz, H12); 7.22 (t, 4H, H1 and H5); 7.26-7.28 (m,
6H, H2, H4 and H8); 7.38 (broad s, 2H, H3).

13C

NMR (125 MHz, CDCl3): δ

24.25 (C19); 25.92 (C18); 55.25 (C17); 57.58 (C16); 65.95 (C15); 77.23 (C7);
114.20 (C11); 114.86 (C12); 129.00 (C9); 124.08 (C10); 128.43 (C2 and C4);
128.81 (C1 and C5); 129.53 (C3); 135.04 (C6); 150.14 (C13); 156.31 (C14);
162.34 (C8).

3.3 Discussion of Synthetic methods
3.3.1 Hydroxylated nickel Schiff base complexes

Nickel Schiff base complexes were synthesized according to a general
literature method.154,155 The hydroxylated Schiff base complexes were first
synthesized by the reaction of different diamines with either 2,5- or 2,3dihydroxybenzaldehyde in order to form the free Schiff base ligand.
Subsequent addition of nickel acetate resulted in formation of the
corresponding nickel complex. The reaction procedure is outlined in Figure
3.1, with complex (2) as an example. The hydroxylated nickel Schiff base
complexes were intensely coloured, and insoluble in common organic
solvents such as methanol, ethanol, and chloroform. They were, however,
soluble in DMSO and DMF.
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Figure 3.1: Reaction scheme for the synthesis of nickel Schiff base complex
(2).

The desired nickel Schiff base complexes were obtained as microcrystalline
powders in good purity and yields (Table 3.1), except for complex (5), which
was contaminated with an excess of free Schiff base ligand. Therefore, it was
purified via crystallisation from MeOH/DMSO before being used as the
starting material for preparing the corresponding alkylated complex.
The structures of all the synthesized nickel Schiff base complexes were
confirmed by using MS, 1H NMR and

13C

NMR spectral data. Further support

for the structures of some of the complexes was provided by X-ray
crystallography, while the purity of the complexes was further assured by
elemental analysis data.
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Table 3.1: Yields of hydroxylated nickel Schiff base complexes.
Nickel
complex
(1)

Structure of diamine

Structure of
dihydroxybenzaldehyde

Yield
(%)
92

(2)

98

(3)

79

(4)

80

(5)

68

(6)

97

Routine 1-dimensional 1H and

13C

NMR spectra were not sufficient to fully

assign the structures of complexes (1)-(6). Therefore, 2D techniques
including COSY (Correlation Spectroscopy), NOESY (Nuclear Overhauser
Effect Spectroscopy), HSQC (Heteronuclear Single-Quantum Correlation)
and HMBC (Heteronuclear Multiple-Bond Correlation) experiments were
employed. The approach taken to assigning the NMR spectra of the
hydroxylated nickel Schiff base complexes is discussed below, using
complexes (2) and (4) as examples. The same process was applied in order
to assign the NMR spectra of all the other hydroxylated complexes.
The proton resonances in the 1H NMR spectra were assigned on the basis of
their chemical shifts, integration, multiplicity and coupling constants. For
example, the 1H NMR spectrum of the Schiff base complex (2) (Figure 3.2)
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exhibited three singlets at 8.82, 8.70 and 6.91 ppm which integrate to two
hydrogen atoms each. As it was expected that the -OH group would give rise
to a very deshielded singlet, the resonance at 8.82 ppm was tentatively
assigned to these protons.

Figure 3.2: 1H NMR spectrum of complex (2).

In addition, since imine groups are electron withdrawing, their protons are
also found at relatively high chemical shifts. Therefore, the singlet at 8.70
ppm was tentatively assigned to the -N=CH protons (H4). The asymmetric
doublet centred at 6.72 ppm appears to be half of an AB pattern arising from
coupled protons with similar chemical shifts. The other half of the AB pattern
is present at 6.91 ppm, but has one of its two resonances obscured by
overlap with another, larger singlet. The AB pattern is tentatively assigned to
H8 and H9, while the most likely assignment for the overlapping singlet is H6.
Evidence for these assignments is provided by the similarity of the chemical
shifts for H6, H8 and H9 in the spectrum of (2), with that of the corresponding
hydrogen atoms in the starting material, 2,5-dihydroxybenzaldehyde. Similar
reasoning led to the conclusion that the two characteristic multiples at 7.29
and 8.13 ppm should be assigned to H1 and H2, respectively. COSY and
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NOESY spectra were then obtained to provide support for the above
assignments as well as complete the identification of resonances to individual
protons in situations where ambiguity remained, e.g. (H1/H2) and
(H6/H8/H9).
COSY NMR spectra contain cross peaks owing to through-bond coupling
interactions between pairs of protons which are two or three bonds apart. For
example, the COSY spectrum of complex (2) (Figure 3.3a) shows two strong
sets of cross-peaks associated with resonances at 7.29 and 8.13 ppm,
consistent with their assignment to H1 and H2. Additional cross-peaks are
present for the AB pattern of signals at 6.72 and 6.91 ppm arising from H8
and H9, as expected. However, COSY is not capable of allowing definitive
assignment of the individual protons within each of the above pairs of
resonances. Therefore a NOESY spectrum was acquired to obtain further
information and complete the assignment.
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Figure 3.3: a) COSY spectrum of complex (2); b) NOESY spectrum of
complex (2). Selected key correlations are highlighted.

NOESY is similar to COSY in that it examines the interactions between
protons in close proximity to each other within the structure of a molecule.
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However, NOESY identifies pairs of protons that are located close to each
other through space, even though they may be several bonds apart. The
NOESY spectrum of complex (2) (Figure 3.3b) shows two strong sets of
couplings involving the imine proton (H4). The first of these also involves the
resonance at 8.13 ppm, allowing it to be identified definitively as H2, and the
signal at 7.29 ppm to H1. The second set of cross peaks involved the
overlapping set of resonances at 6.90 ppm. This provided support for
assigning the intense singlet at this chemical shift to H6. Another, weaker
correlation can be observed between the -OH resonance at 8.82 ppm and
that at 6.92 ppm. The latter was therefore assigned to H8. Additional cross
peaks arising from interactions between H1 and H2, as well as H8 and H9,
are also present in the NOESY spectrum.
The

13C

NMR spectrum of complex (2) (Figure 3.4a) shows ten resonances

which corresponds to the number of distinct carbon environments expected
for this complex. Since the 1H NMR spectrum of (2) had now been fully
assigned, a HSQC spectrum was obtained in an effort to assign each of the
resonances in the

13C

NMR spectrum. The HSQC spectrum in Figure 3.4b

shows correlations between signals in the

13C

NMR spectrum at 115.15,

116.44, 121.07, 127.25, 127.57 and 155.71 ppm, and individual resonances
in the proton spectrum. This enabled the corresponding
resonances to be readily assigned, leaving a further four

13C

13C

NMR

signals to still

be attributed to specific carbon atoms. The latter four resonances did not
show any cross peaks in the HSQC spectrum as they are all due to
quaternary carbon atoms. These were then assigned based on their chemical
shifts. Initially the most upfield of these signals at 119.51 ppm was assigned
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to C5, as it is the only quaternary carbon not directly bound to an O or N
atom. The signal at 142.81 ppm was then assigned to C3 owing to its
proximity to the imine group, while the two other signals at 146.78 and
160.80 ppm were assigned to C7 and C10, respectively. The latter signal is
the most deshielded of all ten resonances owing to being directly attached to
an electronegative oxygen atom, as well as in close proximity to the nickel
cation.

H6

H4
H2

H1

H8

H9

C6
C2

H7

115

C9

b)

120

C1C8

125
130

140
145

F1 (ppm)

135

150

C4

155
160

8 .5

8 .0
F2 (p p m )

7 .5

7 .0

Figure 3.4: a) 13C NMR spectrum of complex (2); b) HSQC spectrum of complex
(2), with C-H correlations highlighted.
68

The NMR spectra of complex (4) were fully assigned using a similar
approach to that used for (2). The 1H NMR spectrum of this complex is
shown in Figure 3.5a, together with an expansion of the aromatic region, for
clarity.

Figure 3.5: a) 1H NMR spectrum of complex (4); b) COSY spectrum of
complex (4). Key correlations are highlighted.

Based on their characteristic chemical shifts, the upfield singlet at 3.43 ppm
was assigned to the aliphatic protons H1, whilst the broad singlet at 8.16 ppm
was assigned to the OH protons. There is also a characteristic downfield
singlet present at 7.88 ppm, which was assigned to the imine proton (H2).
The triplet at 6.38 ppm was assigned to H5, as it was expected to show two
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very similar couplings to H4 and H6. The latter protons gave rise to the two
doublets of doublets at 6.67 and 6.74 ppm, although at this stage it was not
possible to definitively assign these multiplets to individual protons. This
required the use of COSY and NOESY experiments. The COSY spectrum of
complex (4) (Figure 3.5b) showed, as expected, two strong sets of couplings
involving H5, one to H4 and the other to H6. This provided further support for
the assignment of H5 made earlier; however, it still did not allow definitive
assignment of specific 1H resonances to H4 and H6. A strong coupling was
observed between the signal at 6.74 ppm, and that assigned to H2 in the
NOESY spectrum of complex (4) (Figure 3.6). As this coupling was expected
between H4 and H2 owing to their close proximity through space, the signal
at 6.74 ppm was then assigned to H4. This in turn now allowed the other
doublet of doublets at 6.67 ppm to be assigned to H6.

Figure 3.6: NOESY spectrum of complex (4). Key correlations are
highlighted.
70

The

13C

NMR spectrum of complex (4) (Figure 3.7a) showed the expected

number of signals for this complex.

Figure 3.7: a) 13C spectrum of complex (4); b) HSQC spectrum of complex
(4); and c) HMBC spectrum of complex (4), with C-H correlations highlighted.
Two artefacts in the HMBC spectrum are highlighted with arrows.
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Again, a HSQC spectrum (Figure 3.7b) was used to assign those resonances
arising from carbon signals with at least one directly bound hydrogen atom.
By using this approach, resonances at 58.45, 114.81, 114.95, 122.40 and
163.2 ppm could be assigned to specific carbon atoms. The remaining
carbon resonances at 119.60, 148.15 and 153.13 ppm were all therefore
deduced to arise from quaternary carbon atoms, which do not show any
cross-peaks in HSQC spectra. On this occasion, an HMBC spectrum (Figure
3.7c) was obtained in an effort to assign these signals. HMBC spectra reveal
correlations between carbon and hydrogen nuclei which are typically
separated by two or three bonds within a molecule, and may in some
instances be separated by four or more bonds in conjugated systems.
The HMBC spectrum in Figure 3.7c shows cross peaks between the

13C

resonance at 163.21 ppm assigned to C2, and 1H resonances previously
assigned to H1 and H4. In addition, two sets of artefacts are present in the
spectrum, one at lower field which is due to the one-bond correlation
between C2 and H2, and another at higher field, which is due to the onebond correlation between C5 and H5. Figure 3.7c also shows two or three
cross peaks for each of the quaternary carbon signals identified above. Of
these, the resonance at 119.60 ppm was tentatively assigned to C3 in view of
its more shielded chemical shift, which is consistent with this carbon atom not
being directly attached to a highly electronegative atom. Evidence supporting
this assignment was provided by the two cross peaks in the HMBC spectrum
involving the resonance at 119.60 ppm, and those from H2 and H5. These
cross peaks were expected, as C3 is two bonds away from H2, and three
bonds away from H5. While C8 is also expected to show a strong cross peak
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with H2, it would not be expected to do so with H5 which is four bonds
distant. In addition, C8 would be expected to give a less shielded resonance
owing to its proximity to both Ni and O atoms. Therefore the

13C

resonance at

119.60 ppm was assigned to C3, despite the surprising absence of a cross
peak with H4 in the HMBC spectrum. The

13C

resonance at 153.15 ppm was

then assigned to C8, primarily on the basis of the observed cross peak with
H2. In addition, this

13C

signal showed cross peaks with resonances from

both H4 and H6. The remaining quaternary carbon resonance at 148.15 ppm
was therefore assigned to C7, and as expected showed cross peaks with the
resonances arising from protons H5 and H6.

3.3.2 Alkylated nickel Schiff base complexes

The nickel Schiff base complexes used for DNA binding studies were
prepared by reacting the hydroxylated nickel Schiff base compounds with 1(2-chloroethyl)piperidine hydrochloride in the presence of K2CO3. This
reaction was performed using DMF as the solvent, under an inert
atmosphere of nitrogen gas. Figure 3.8 summarises the conditions used for
these reactions by using the synthesis of complex (8) from (2) as an
example.
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Figure 3.8: Reaction scheme for the synthesis of nickel Schiff base complex
(8).

The alkylated nickel Schiff base complexes were synthesised according to a
modified literature method.154 In all cases with the exception of the procedure
for preparing complex (12), the concentration of the hydroxylated precursor
complex was 0.03 mM, instead of the 0.01 mM stated in the literature
method. In addition, although the desired alkylated nickel Schiff base
complexes precipitated as a coloured solid over the course of reaction, they
were not isolated immediately by filtration. Instead all of the DMF present in
the reaction mixture was removed by applying heat under vacuum, and any
unreacted starting material was subsequently removed by washing with
water several times. It was found that this isolation procedure improved the
overall yield of each of the complexes. The yields obtained for each of the
alkylated complexes synthesised are summarised in Table 3.2.
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Table 3.2: Yields of alkylated nickel Schiff base complexes.
Nickel
complex
(7)

Structure of
diamine

Structure of
diamine

Structure of alkyl
group

Yield
(%)
63

(8)

53

(9)

-

(10)

53

(11)

26

(12)

46

The structure of all alkylated nickel complexes was confirmed using ESI-MS
as well as a suite of 1D and 2D 1H and

13C

NMR spectroscopic techniques.

The procedure employed to fully assign the 1H and

13C

NMR spectra of a

typical complex is described below, using (8) as an example.
Figure 3.9 illustrates the full

1H

NMR spectrum of complex (8), with

expansions of the upfield and downfield regions of the spectrum showing the
assignments of individual protons.
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Figure 3.9: 1H NMR spectrum of complex (8).

In the aromatic region of the spectrum, two distinctive multiplets are present
at 7.19 and 7.70 ppm, which strongly resemble signals assigned to H1 and
H2 in the spectra of related complexes also containing the phenylenediamine
unit. The COSY spectrum of (8) (Figure 3.10) shows that the above two
multiplets are coupled to each other, but to no other

1H

resonances,

providing support for the same assignment in the case of the current
complex. Identification of which of the two resonances should be assigned to
H1, and which to H2, was then achieved using NOESY spectroscopy. The
key to this assignment was knowing that the most deshielded 1H resonance
in the entire spectrum was assigned to the imine hydrogen atom, H4.
Inspection of the NOESY spectrum (Figure 3.11) shows a clear cross peak
involving H4 and the resonance at 7.70 ppm, identifying the latter as H2, and
therefore also enabling the assignment of the 1H resonance at 7.19 ppm to
H1.
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Figure 3.10: a) Expanded view of the aromatic region of the COSY
spectrum of complex (8); b) Expanded view of the aliphatic portion of the
COSY spectrum of complex (8) selected key correlations are highlighted.
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Also apparent in the aromatic region of the 1H NMR spectrum is a set of
three multiplets shown by the COSY spectrum to be due to a set of three
coupled protons. The first of these is a doublet at 6.67 ppm with a coupling
constant of 2.6 Hz, which is indicative of meta proton coupling, as expected
for H6 owing to the effect of H8 located four bonds away. The remaining
signals strongly resemble an AB pattern, in which the two upfield resonances
centred at 7.02 ppm have been further split into doublets with the same
coupling constant as that found for H6. These upfield signals were therefore
assigned to H8. The larger coupling for H8 was equal to 9.4 Hz, which is as
expected identical to that observed for the other two resonances in this AB
pattern, centred at 7.09 ppm, which were therefore assigned to H9. These
assignments were supported by the pattern of cross peaks observed for this
group of three multiplets in the COSY spectrum.

Figure 3.11: NOESY spectrum of complex (8), with key correlations
highlighted.
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Because of their aliphatic character, the proton signals for the piperidine
groups all appear in the upfield region of the 1H NMR spectrum. The two
characteristic triplets at 2.75 and 4.04 ppm integrate to four protons each.
Therefore, based on their chemical shifts, integration and splitting pattern,
they were assigned to H12 and H11, respectively. Evidence in support of
these specific assignments was provided by the NOESY spectrum (Figure
3.11), which showed a clear cross peak between H6 and the triplet at 4.04
ppm. This indicates that the latter multiplet must arise from H11, as it is the
nearer of the two methylene groups to H6. This left three resonances in the
1H

spectrum at 1.50, 1.60 and 2.51 ppm, which required assignment. The

first of these could be readily assigned to H15, owing to its smaller integration
compared to that of the two other resonances, as well its chemical shift. The
multiplet at 1.60 ppm was coupled to each of the other two multiplets arising
from the piperidine group in the COSY spectrum, allowing it to be assigned to
H14, and leaving the last broad signal at 2.51 ppm to be assigned to H13.
This signal was the most deshielded of the 1H resonance arising from the
piperidine group, owing to the proximity of H13 to an electronegative nitrogen
atom.
The

13C

NMR spectrum of complex (8) is presented in Figure 3.12a, and

showed the expected number of signals. An HSQC spectrum was also
obtained to facilitate assignment of resonances due to carbon atoms with at
least one hydrogen attached. For example, the

13C

signals at 24.35, 26.09

and 55.23 ppm could be assigned to C15, C14 and C13, respectively.
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Figure 3.12: a) 13C NMR spectrum of complex (8); b) HSQC spectrum of
complex (8); c) HMBC spectrum of complex (8), with C-H correlations
highlighted.

80

In addition, the two carbon resonances at 127.92 and 127.59 ppm show
cross peaks with proton resonances which were assigned to H1 and H8,
respectively, thereby allowing the assignment of the former

13C

signals to C1

and C8. Some carbon resonances did not exhibit any HSQC cross peaks
owing to the fact they arise from quaternary carbon atoms, and therefore
required a HMBC spectrum in order to facilitate their assignment. The HMBC
spectrum in Figure 3.12c shows two or three cross peaks for each of the four
carbon resonances identified as arising from quaternary carbon atoms. Of
these, the most shielded is at 118.56 ppm. This suggests that this resonance
should be assigned to C5, as it is the only one of the four quaternary carbon
atoms not directly bonded to an O or N atom. Evidence in support of this
assignment is provided by the presence of cross peaks in the HMBC
spectrum involving H4, which is located only two bonds from C5, and H9.
Perhaps surprisingly, there was no cross peak involving C5 and H6, which
are also only two bonds distant. The next most shielded quaternary carbon
resonance is present at 142.89 ppm, and shows cross peaks in the HMBC
spectrum with the 1H signals arising from H2 and H4. Such cross peaks were
expected for C3, as it is two bonds away from H2, and three bonds away
from H4. Therefore the signal at 142.89 ppm was assigned to C3. The two
remaining quaternary carbon resonances are at 149.18 and 162.80 ppm. The
first of these showed cross peaks in the HMBC spectrum with H6, H8 and
H9, while for the second cross peaks involving H4, H6, H8 and H9 were
observed. These two carbon resonances were assigned to C7 and C10,
respectively. The observation of a cross peak with H4 was strong evidence in
favour of assigning the

13C

resonance at 162.80 ppm to C10, as this
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hydrogen atom is located three bonds away from C10, but is four bonds
away from C7. Therefore a strong cross peak would not be expected for C7
and H4.
The fully assigned 1H NMR spectrum of complex (10) is presented in Figure
3.13, with expansions of both the aromatic and aliphatic regions also shown
for clarity. The procedure followed to assign the proton resonances present in
the aromatic portion of the spectrum was identical to that used for assigning
signals in the corresponding region of the spectrum of (4) (Section 3.3.1),
and will therefore not be discussed here. In addition, the assignment of
resonances in the aliphatic region of the spectrum was accomplished using a
similar approach to that followed for complex (8), which also contains two
piperidine groups.

Figure 3.13: 1H NMR spectrum of complex (10).
82

The remaining assignments shown in Figure 3.13 were made with the
support of information provided by the COSY and NOESY spectra illustrated
in Figure 3.14 and Figure 3.15, respectively. Both of the latter spectra
contained cross peaks reflecting the existence of similar coupling patterns to
those observed in the corresponding spectra of complexes containing similar
structural moieties to (10). For example, the aromatic region of the 1H and
COSY NMR spectra of (4) and (10) both contain two doublets and a triplet
attributable to H4, H5 and H6.

Figure 3.14: COSY spectrum of complex (10). Key correlations are
highlighted.
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Figure 3.15: NOESY spectrum of complex (10). Key correlations are
highlighted.

Figure 3.16a presents the

13C

NMR spectrum of complex (10), which

contained the expected number of carbon signals. Assignment of the carbon
signals in the aromatic region of the spectrum was based on a comparison of
their chemical shifts to those of

13C

resonances in the spectrum of complex

(4), while the carbon signals in the aliphatic portion were assigned after
comparing their chemical shifts to those of

13C

resonances in the spectrum of

complex (8). These assignments were supported by analysis of the HSQC
spectrum of (10) shown in Figure 3.16b. For example, the presence of cross
peaks for 1H resonances assigned to H10 and H1, with the two close carbon
signals at 57.61 and 58.54 ppm, allowed the latter resonances to be
assigned to C10 and C1, respectively. The
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13C

NMR resonance at 124.14

ppm was similarly assigned to C4 owing to the presence of a cross peak
involving H4. By using the remaining HSQC cross-peaks, all the protonated
carbon resonances were subsequently assigned.
Long range C-H correlations were used to assign the remaining signals in the
13C

spectrum. The HMBC spectrum in Figure 3.16c shows cross peaks which

involved the carbon resonance at 120.18 ppm, and those from H2 and H5.
This enabled the

13C

resonance to be assigned to C3, as it is positioned two

bonds away from H2, and three bonds away from H5. In addition, the

13C

resonance at 149.95 ppm exhibited cross peaks with resonances from H5,
H6 and H9. Consequently this

13C

resonance was assigned to C7, allowing

the only remaining unassigned carbon resonance, at 155.83 ppm, to be
assigned to C8. Consistent with this assignment, the spectrum showed cross
peaks involving this 13C resonance and those from H2, H4 and H6.
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Figure 3.16: a) The 13C NMR spectrum of complex (10); b) HSQC spectrum
of complex (10) ; c) HMBC spectrum of complex (10). Key correlations are
highlighted.
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3.4 Crystallographic Data

Single-crystal X-ray diffraction analyses and structure determinations were
performed by Dr. Anthony Willis, of the Research School of Chemistry,
Australian National University. Crystals of complex (5) suitable for singlecrystal X-ray analysis were obtained by slow evaporation from a
methanol/DMSO solvent mixture. Crystals of (8) were obtained by slow
diffusion of diethyl ether into a solution of (8) in DCM. Crystals of (10) were
obtained by slow evaporation from a DCM/ petroleum spirit (1:3) solvent
mixture. ORTEPs showing the solid state structures of these complexes and
the numbering systems for the non-hydrogen atoms, are presented in Figure
3.17. Details of collected crystallographic data and structural refinements for
the three complexes are summarised in Table 3.3.
.
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(5)

(10)

(8)

Figure 3.17: ORTEPs for the molecular structures of complexes (5), (8) and (10).
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Table 3.3: Summary of crystallographic data for complexes (5), (8) and (10).
(5)

(8)

(10)

Formula

(C20H14N2NiO4)3H2O

C34H40N4NiO4·H2O

C30H40N4NiO4H2O

M

1233.18

645.44

597.40

Crystal system

Triclinic

Triclinic

Monoclinic

Space group

P-1

P-1

P21/n

a (Å)

12.2000(4)

8.1440 (1)

10.1567(3)

b (Å)

15.0224(5)

11.8552 (2)

8.5596(4)

c (Å)

15.4129(6)

15.6018 (3)

33.2575 (13)

α (˚)

74.102(3)

93.0064 (17)

-

β (˚)

71.068 (3)

90.4792 (16)

98.602 (3)

γ(˚)

69.971(3)

90.5565(15)

-

V (Å3)

2467.88(16)

1504.13 (4)

2858.79(19)

Dx (Mg m-3)

1.659

1.425

1.388

Z

2

2

4

Number of unique reflections

12283

8259

8148

Refinement

R[F2 > 2σ (F2) ] = 0.058

0.030

0.060

wR(F2) = 0.106

0.074

0.106
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It was observed that the nickel ion in all three crystal structures has adopted
a square planar coordination geometry. All bond lengths and angles involving
the central nickel ions (Table 3.4) are consistent with standard values.155,156
The arrangement of the phenylenediamine moieties in (5) and (8) results in
N2-C9-C8-N1 torsion angles of 4.21(5)° and -2.42(15)°, respectively. In
contrast, the arrangement of the ethylenediamine moiety in complex (10)
results in the same torsion angle increasing to -38.02 (3)°.

Table 3.4: Selected bond lengths (Å) and angles (°) for nickel Schiff base
complexes.
Bonds

(5)

(8)

(10)

Ni-O1

1.847(2)

1.8320 (9)

1.8674(17)

Ni-O2

1.843(3)

1.8354 (9)

1.8717(19)

Ni-N1

1.855(3)

1.8557 (11)

1.855(2)

Ni-N2

1.862(3)

1.8512 (10)

1.855(2)

O1-Ni-O2

83.82(11)

83.07 (4)

86.49(8)

O2-Ni-N2

95.12(12)

95.44 (4)

94.17(9)

O1-Ni-N2

178.25(12)

177.84 (4)

175.35(9)

O2-Ni-N1

178.58(12)

177.81 (4)

175.42(9)

O1-Ni-N1

94.76(12)

95.17 (4)

94.55(9)

N1-Ni-N2

86.29(13)

86.35 (5)

85.16(10)

Complex (5) crystallised in a triclinic crystal system with space group P-1.
Three molecules of the Schiff base complex called (5A), (5B) and (5C) were
present, with the central nickel ions labelled Ni1, Ni2 and Ni3, respectively.
One water molecule was also present in the asymmetric unit. Both oxygen
atoms coordinated to the nickel atom of (5A) were participating in hydrogen
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bonding interactions with the oxygen atom on the lattice water molecule, with
the distances for O1-O13 and O2-O13 being 2.83 (6) and 2.91 (6) Å,
respectively. In addition, both the phenolic and the coordinated oxygen atoms
of the neighbouring (5B) and (5C) molecules were sufficiently close to one
another to enable intermolecular O–H···O hydrogen bonds to form, with the
distances for H11-O6, H12-O6, H7-O9, and H8-O9 being 2.14, 2.09, 2.11
and 2.10 Å, respectively.
In the crystal lattice of (5) (Figure 3.18), molecules (5A) and (5B) are
arranged in a twisted co-facial manner which results in close contacts
between carbon atoms on the benzylic and phenylenediamine moieties of
separate nickel molecules. As a result the bond distances for the C6-C31,
C10-C38, C11-C39, and C18-C26 contacts involving carbon atoms on
molecules (5A) and (5B) were 3.39, 3.31, 3.34, and 3.35 Å, respectively
(Figure 3.18a). Molecules (5B) and (5C) assemble in such a way to produce
short contacts between the benzylic carbons on one molecule, and the
phenolic oxygens on the adjacent molecule. This results in distances for C36O11, C36-O12, C41-O7 and C41-O8 equal to 3.35(5), 3.13(4), 3.27(4) and
3.38(5) Å, respectively. The most notable contact between (5B) and (5C)
involved Ni3 and the phenolic oxygen O7, which were located 3.30 Å apart
(Figure 3.18b). The only contact observed between complexes (5A) and (5C)
was between the phenolic oxygen atom O11 on complex (5A) and the
hydrogen atom H71, which is bonded to C7 on complex (5C), at a distance of
2.59 Å.
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(a)

(b)

(c)

Figure 3.18: Different perspectives of the stacking of the three nickel
complexes in the lattice of complex (5): a) all three nickel complexes in the
crystal lattice; b) the short contacts between complexes (5A) and (5B); c) the
short contacts between (5B) and (5C). Some hydrogen atoms were omitted
for clarity.
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Complex (8) also crystallised in the triclinic space group P-1, but with one
metal complex and one water molecule in the asymmetric unit. There were
hydrogen bonds between the oxygen atoms coordinated to the nickel ion,
and the oxygen atom on the water molecule, with the distances for H1-O1
and H1-O2 being 2.21 (3) Å and 2.36 (3) Å, respectively. In contrast, complex
(10) belongs to the monoclinic crystal system with the space group P21/n.
One full metal complex and one H2O molecule comprise the asymmetric unit
of the structure of (10). The oxygen atoms coordinated to the nickel ion and
the phenolic oxygen atoms are involved in hydrogen bonding interactions
with the hydrogen atoms of the lattice water molecules, with the distances for
H1-O1, H1-O3, H2-O2 and H2-O4, being 2.36, 2.36, 2.49, and 2.31 Å,
respectively.
In the crystal lattice of (8), the two nickel Schiff base molecules possess a
crystallographic inversion centre, and they are arranged in a slipped co-facial
manner (Figure 3.19). The same arrangement has been previously reported
in the crystal lattice of the complex N,N′-bis-4-(hydroxysalicylidine)mesodiphenylethylenediaminenickel(II).156 The shortest intermolecular distance
between the two molecules in the solid state structure of (8) is that between
the nitrogen atom N1 (coordinated to the nickel ion) and carbon atom C16 on
the benzylic moiety. These two atoms were located 3.27(16) Å apart.
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Figure 3.19: Perspective view of the stacking of pairs of complexes in the
lattice of complex (8).

The structure of complex (10) was distinctly bowed around the central
coordination environment (Figure 3.20). As a consequence the six membered
chelate rings coordinated to the nickel ion are not completely coplanar with
each other. This is shown by the angle of 11.01° between the Ni1-O1-C1-C6C7-N1 and Ni1-O2-C16-C11-C10-N2 planes. For comparison, the angles
between the same planes in complexes (5) and (8) were only 0.57° and
2.21°, respectively.
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Figure 3.20: View of complex (10) highlighting the non co-planar
arrangement of the six membered chelate rings around the nickel ion. The
ethyl piperidine moieties were omitted for clarity.

Two molecules in the unit cell of complex (10) are related by a
crystallographic inversion centre and assemble in a co-facial manner (Figure
3.21). The same arrangement was previously reported to be present in the
solid state structure of the complex (15), and results in the two nickel
complexes sit neatly on top of one another

156

This arrangement results in short contacts between the aliphatic carbon atom
C9 of the ethylenediamine moiety and the two nickel-coordinated oxygen
atoms O1 and O2 in the adjacent molecule. These pairs of atoms were found
to be 3.28(3) and 3.27(3) Å, respectively apart. The shortest intermolecular
distance between the two molecules is 3.19 Å between the two nickel ions.
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Figure 3.21: Perspective view of the stacking of pairs of complexes in the
lattice of complex (10).
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CHAPTER 4
DNA BINDING EXPERIMENTS
4.1 Introduction
The ability of the nickel “salphen” complexes, which were prepared via a
procedure that employed 2,4- dihydroxybenzaldehyde, to bind to the dsDNA
molecule D2, and the tetramolecular quadruplex Q4, has been investigated
previously using ESI-MS, CD spectroscopy and UV melting temperature
measurements.156,157 It was found that the presence of the aromatic system
in the “top” of the nickel Schiff base complexes may have enabled partial
insertion of the nickel molecules between the base pairs of the dsDNA. In
contrast, the extent of binding of nickel Schiff base complexes containing
either the meso-1,2-diphenylethylenediamine moiety in the “top” of the Schiff
base to dsDNA was far less extensive. Both classes of nickel molecules
exhibited significant levels of binding to both tetramolecular and unimolecular
quadruplex DNA molecules. Examining the effect of changing the length and
chemical composition of the pendant groups in nickel Schiff base complexes
on their DNA-binding properties has also been previously explored.155-157 It
was found that changing the length of the alkyl group connecting the
piperidine rings to the Schiff base sometimes had a small effect on affinity
towards either dsDNA or qDNA. Changing the piperidine groups to
morpholines did not result in any enhancements in DNA affinity or selectivity.
To date the effect of varying the position of the pendant groups on the Schiff
base on the ability of the nickel complexes to bind to qDNA, as well as their
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selectivity for qDNA over dsDNA, has not been explored. This chapter
presents the results of ESI-MS and CD spectroscopic studies designed to
determine whether such structural changes have a significant effect on DNAbinding properties.

4.2 Results and discussion
4.2.1 DNA binding experiments performed using nickel
complexes containing the 1,2-phenylenediamine moiety
Initially, the DNA-binding properties of the three isomeric nickel complexes
containing a single aromatic ring in the “top” of the Schiff base ligand was
explored. The structures of these complexes are shown in Figure 4.1.
Complex (14) has been shown in a number of studies to have significant
affinity for different types of DNA.155,156
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Figure 4.1: Structures of nickel Schiff base complexes containing the 1,2phenylenediamine moiety, with ethyl piperidine pendant groups attached at
different locations on the Schiff base.

In the first instance ESI mass spectra were obtained using solutions
containing different ratios of the three nickel Schiff base complexes shown in
Figure 4.1 and the dsDNA molecule D2 (Table 2.1). Figure 4.2 shows the ESI
mass spectra of a solution containing D2 alone, as well as those containing
different ratios of D2 and complex (8), which was prepared by a synthetic
procedure that used 2,5-dihydroxybenzaldehyde in the first step.
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Figure 4.2: Negative ion ESI mass spectra of solutions containing D2 and
different ratios of (8). (a) Free D2; (b) D2:(8) = 1:1; (c) D2:(8) = 1:3; (d) D2:(8)
= 1:6; (e) D2:(8) = 1:9.  = free D2;  = [D2 + (8)];  = [D2 + 2(8)];  = [D2
+ 3(8)];  = [D2 + 4(8)]; = [D2 + 5(8)]; = [D2 + 6(8)].

The ESI mass spectra of free D2 (Figure 4.2a) contains ions at m/z 1626.5
and 1952.0, which are attributed to [D2 - 6H]6- and [D2 - 5H]5-, respectively.
The addition of (8) to D2 led to the appearance of new ions with an overall
charge of either 6- or 5-, which correspond to non-covalent complexes
containing one or more intact nickel molecules bound to D2. For example, in
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Figure 4.2b, ions of low abundance with a 6- overall charge appear at m/z
1731.2, and are attributable to non-covalent complexes containing one nickel
molecule bound to D2. These may be described as [D2 + (8)]. The same
non-covalent complex also gave rise to ions with an overall charge of 5- and
very low abundance at m/z 2077.7. Examination of the spectra in Figure
4.2a-d shows that the relative abundance of ions from [D2 + (8)] increased as
the D2:(8) ratio was increased, whilst at the same time the relative
abundance of ions from free D2 decreased. This trend is consistent with
more extensive formation of non-covalent complexes as the amount of (8) in
solution was increased. Further evidence of this is provided by the
appearance of ions with a 6- charge and very low abundance in Figure 4.2b
at m/z 1835.8, which are assigned to [D2 + 2(8)]. The relative abundance of
these ions increased steadily as the ratio of (8) with respect to D2 became
greater, and they were the ions of greatest abundance in the spectrum of a
solution containing a D2:(8) with a ratio of 1:9. Concurrently, ions
corresponding to non-covalent complexes consisting of higher numbers of
nickel molecules bound to D2 were also seen in medium to high abundance.
This includes ions with a 6- charge at m/z 1940.4 and 2045.2, which can be
assigned to [D2 + 3(8)] and [D2 + 4(8)], respectively. Furthermore, the
spectrum of a solution containing a 1:9 ratio of D2:(8) (Figure 4.2e), showed
6- ions of very low abundance at m/z 2149.5 and 2253.6, which can be
assigned to non-covalent complexes consisting of five and six nickel
molecules bound to D2, respectively.
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In summary, the spectra in Figure 4.2 show that the abundance of ions
corresponding to non-covalent complexes consisting of increasingly larger
numbers of nickel molecules bound to D2 grew as the amount of (8) in
solution was increased. At the same time ions from free D2 diminished in
abundance as expected. Similar trends were observed for ESI mass spectra
of solutions containing D2 and the analogous complexes (14) and (11),
confirming the ability of the latter nickel complexes to also bind to D2. This
was not a surprising result in the case of complex (14), as its ability to form
non- covalent complexes with this dsDNA has been previously reported. 156 In
order to compare the binding affinity of complexes (8), (11) and (14) towards
D2, a series of spectra were obtained of solutions containing the same ratio
(1:6) of D2 and the nickel complexes. These spectra are shown in Figure 4.3.
In each spectrum, ions at m/z 1626.5 and 1952.0 are present which are
attributable to free dsDNA. However, the abundances of these ions vary from
one spectrum to another, suggesting that the nickel complexes are binding to
different extents to the DNA. For example, ions at m/z 1626.5 from D2 are of
lowest abundance in Figure 4.3d, which is a spectrum of a solution
containing a 1:6 ratio of D2 and (14). This supports the hypothesis that (14)
has a higher affinity towards D2 than either (8) or (11). Evidence in support of
this is provided by the observation that the abundance of ions from noncovalent complexes containing three, four or five nickel complexes bound to
D2 appears to be slightly greater in the case of the spectrum shown in Figure
4.3d. Therefore it appears that complex (14), which was prepared via a
synthetic pathway which employed 2,4-dihydroxybenzaldehyde, has the
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highest affinity of the three isomeric complexes for D2. In this thesis, “affinity”
is used to describe the overall binding of a nickel complex for a DNA
molecule based on observation of the amounts of free DNA observed and the
number of nickel molecules bound. There may, however, be different binding
modes as more nickel molecules bind, and/or binding of each successive
nickel molecule may or may not be independent.

100



(a)

0



Relative intensity (%)

100



(b)










0



100





(c)


  





0



100





(d)












0
1600

1800

2000

2200

2400

m/z
Figure 4.3: Negative ion ESI mass spectra of solutions containing D2 and
different nickel Schiff base complexes at a 1:6 ratio. (a) Free D2; (b) D2 + (8);
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(c) D2 + (11); (d) D2 + (14).  = free D2;  = [D2 + (Ni)];  = [D2 + 2(Ni)]; 
= [D2 + 3(Ni)];  = [D2 + 4(Ni)]; = [D2 + 5(Ni)].

The spectra in Figure 4.3b and c also show ions of medium or high
abundance from non-covalent complexes consisting of two or three nickel
complexes bound to D2, as well as ions of lower abundance from noncovalent complexes containing greater numbers of bound nickel molecules.
Therefore it appears that changing the location of the ethyl piperidine groups
on the Schiff base complexes had little effect on the ability of (14) to bind to
and form non-covalent complexes with D2.
Inspection of Figure 4.3 suggests that the order of binding affinity of these
three nickel complexes for D2 is: (14) > (8) > (11). However, in order to
confirm this conclusion, it was necessary to calculate and compare the
relative abundances of ions from free D2 and different types of non-covalent
complexes seen in all three spectra. Therefore the relative abundances were
calculated by adding the individual abundances of all ions assigned to free
DNA or a specific non-covalent complex in a given spectrum, and dividing the
result by the sum of the abundances of all ions present in that spectrum.
Figure 4.4 shows how the relative abundances of ions varied from the
spectrum of one solution to another. The figure shows that complex (14)
binds the most extensively to D2, as the relative abundances of ions from
non-covalent complexes consisting of two, three or four molecules of (14)
bound to D2 are greater than for the corresponding ions containing either of
the two other nickel complexes.
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Figure 4.4: Relative abundances of ions in spectra of solutions containing D2
and different nickel Schiff base complexes at a 1:6 ratio.

In addition, Figure 4.4 also shows that the relative abundances of ions from
non-covalent complexes consisting of one or four molecules of (8) or (11)
bound to DNA is essentially identical. However, the relative abundances of
ions from non-covalent complexes containing two molecules of (8) bound to
D2 is greater than that for the corresponding non-covalent complexes
containing (11). This observation, along with a lower relative abundance of
ions from D2, suggests that the affinity of (8) is slightly greater than that of
(11). Therefore the results illustrated in Figure 4.4 support the order of
binding affinity proposed earlier for these three complexes: (14) > (8) > (11).
Overall the extent of non-covalent complex formation with D2 did not vary
greatly between the three nickel complexes, suggesting that the position of
the ethyl piperidine moiety does not have a major impact on affinity towards
dsDNA for this subset of nickel Schiff base complexes. In order to test this
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hypothesis further, CD spectra were obtained of solutions containing different
ratios of the three nickel Schiff base complexes and D2, and are presented in
Figure 4.5.
Circular dichroism (CD) spectroscopy is routinely used along with other
techniques such as FTIR difference spectroscopy, ESI-MS and UV-visible
absorption spectrophotometry, to study conformational changes of DNA.165168

The CD signal of normal (B-form) DNA arises from the asymmetric carbon

atoms present in the sugar residues, and its helical structure. Changes to the
CD spectrum of DNA may be brought about as a result of conformational
changes resulting from the binding of different compounds, or a change in
the surrounding solution conditions. Depending on the mode or extent of
binding of a small molecule, DNA can either remain in its original structure, or
may transform into another secondary structure such as A-form or Z-form
DNA. Each of these secondary structures gives rise to a distinct spectrum
featuring CD bands at different wavelengths.166,169,170 In addition, it is
possible to provide evidence in support of the binding modes used by small
molecules to bind to DNA, such as intercalation, groove binding and
electrostatic interaction, by monitoring the changes in intensity and position
of CD bands.171-174 Therefore, CD spectroscopy is considered to be one of
the most powerful techniques for providing information about the nature of
interactions between metal complexes and dsDNA.
The CD spectra presented in Figure 4.5 show the effect of addition of
increasing amounts of each of the three nickel complexes upon the CD
spectrum of D2. The spectrum of a solution containing only free D2 shows
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large positive and negative CD bands centred at 282 nm and 249 nm,
respectively. These values are characteristic for B-form DNA.166 The addition
of the metal complexes to the DNA resulted in changes to the ellipticity and
positions of the CD bands, which are summarised in Table 4.1.
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Figure 4.5: Circular dichroism spectra (200-400 nm) of solutions containing
D2 and different ratios of nickel Schiff base complexes. (a) D2 + (8); (b) D2 +
(11); (c) D2 + (14).

Table 4.1: Effect of addition of nickel Schiff base complexes on the CD
spectrum of D2.*
Nickel
Positive CD band at 282 nm Negative CD band at 249 nm
complex
Δλ (nm)
Δɛ (mdeg)
Δλ (nm)
Δɛ (mdeg)
(8)
1.9
-1.5
-2.6
2.2
(11)
0.7
-1.5
1.5
0.4
(14)
-2.0
-1.9
-0.5
4.0
* All Δλ and Δε values are the difference between the values for free DNA
and those for a solution containing a DNA:nickel complex ratio of 1:9.
Negative Δλ values indicate a blue shift; positive values indicate a red shift.
Δε values are the difference between εmax for this CD band for the solution
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containing no metal complex, and εmax for the same CD band for the solution
with the highest DNA:nickel complex ratio.
Inspection of Figure 4.5c suggests that overall the addition of (14) to D2
caused the largest changes to the CD spectrum of D2, whereas the addition
of (11) resulted in the smallest changes (Figure 4.5b). These conclusions are
reinforced by the results presented in Table 4.1. The most notable effect
caused by addition of a nickel complex was the change in ellipticity of the
negative CD band upon addition of (14). Addition of 9 equivalents of this
nickel complex more than doubled the initial ellipticity of this CD signal.
Furthermore, the change in ellipticity caused by addition of (14) was almost
double that observed upon addition of the same amount of (8), and 10 times
larger than that seen with complex (11). Addition of (14) also resulted in a
slightly larger change to the ellipticity of the positive CD band than that
caused by either (8) or (11). It is also worthwhile noting that addition of (14)
resulted in a small blue shift for the positive CD band of D2, whereas the
other two nickel complexes had the opposite effect, possibly indicating subtle
differences in their modes of interaction. Inspection of Table 4.1 shows that
the magnitude of changes to the position and ellipticity of both CD bands
generally increased in the order: (14) > (8) > (11), which is the same as the
order of increasing binding affinities derived from the ESI-MS studies
presented earlier.
In order to investigate the binding of (8), (11) and (14) to tetramolecular
quadruplex DNA, a similar series of ESI-MS and CD experiments to those
described above, was also performed with Q4 (Table 2.1). Figure 4.6 shows
the ESI mass spectra of solutions containing a 1:6 ratio of Q4 and (8), (11) or
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(14). The spectrum of a solution containing Q4 alone (Figure 4.6a), contains
ions of low and high abundance at m/z 1675.1 and 2010.4, which are
assigned to [Q4 + 4NH4+ - 10H]6- and [Q4 + 4NH4+ - 9H]5-, respectively. The
presence of four ammonium ions in these ions in not surprising, and provides
support for the conclusion that the tetramolecular quadruplex structure
initially formed in solution has been successfully transferred to the gas
phase. This is because Q4 contains five G-tetrads, and would therefore be
expected to trap four unimolecular cations in between each quartet. Since the
mass spectra were obtained using solutions of Q4 in ammonium acetate, it is
not surprising that those four unimolecular cations were all ammonium ions.
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Figure 4.6: Negative ion ESI mass spectra of solutions containing Q4 and
different nickel Schiff base complexes at a 1:6 ratio. (a) Free Q4; (b) Q4 +
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(8); (c) Q4 + (11); (d) Q4 + (14).  = free Q4;  = [Q4 + (Ni)];  = [Q4 +
2(Ni)];  = [Q4 + 3(Ni)];  = [Q4 + 4(Ni)]; = [Q4 + 5(Ni)].
After addition of the nickel Schiff base complexes, none of the spectra
showed ions from free DNA. This observation suggests that each of the three
complexes has a significant affinity towards Q4, and is in contrast with what
was observed for D2 (Figure 4.3). Further examination of Figure 4.6b-d
reinforces this view. For example, each of the spectra in Figure 4.6b and d
contain ions of high abundance at m/z 2261.7, which correspond to [Q4 +
2(Ni) + 4NH4+ - 13H]5-, which may be more simply stated as [Q4 + 2(Ni)]. In
addition, ions of low to medium abundance are present at m/z 2387.3, which
are attributable to [Q4 + 3(Ni)]. These observations confirm that each of the
isomeric nickel complexes exhibits a significant and similar degree of affinity
towards Q4. In order to determine the order of binding affinities towards this
qDNA molecule, the relative abundances of each of the ions observed was
calculated, and is presented in Figure 4.7. Inspection of the figure shows that
the only nickel complex to form non-covalent complexes with Q4 that
involved five bound nickel molecules was (11). This observation, combined
with the slightly higher abundances of ions from [Q4 + 3(11)] and [Q4 +
4(11)], compared to the corresponding ions containing either (8) or (14),
suggests that (11) may have the highest overall affinity of the nickel
complexes for this tetramolecular quadruplex. Examination of Figure 4.7 also
reveals that while the relative abundances of ions from [Q4 + 2(Ni)] is greater
for (14) than for (8), the converse is true in the case of ions arising from [Q4
+ 3(Ni)]. This suggests that (8) and (14) have very similar affinities for Q4,
and therefore the overall order of binding affinity of these three complexes is:
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(11) > (8) ≈ (14). This order is essentially the reverse of what was obtained
from studies involving the dsDNA molecule D2. It therefore appears that the
nature and extent of binding modes used by the nickel complexes with the Gquadruplex DNA molecule may be slightly different to those used in
interactions with dsDNA.
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Figure 4.7: Relative abundances of ions in ESI mass spectra of solutions
containing Q4 and different nickel Schiff base complexes at a 1:6 ratio.

Comparison of Figure 4.4 and Figure 4.7 shows that the abundances of ions
from free D2 in the spectra of solutions containing a nickel complex and this
DNA molecule were between 4 and 22 %, while ions from free Q4 were
absent in the spectra of solutions containing a nickel complex and this
tetramolecular G-quadruplex. This indicates that while complexes (8), (11)
and (14) interact with both types of DNA, the extent of binding is greater in all
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cases with Q4. It is also worth reflecting on the observation that although 6
equivalents of nickel complexes were added to the solutions used to obtain
the spectra shown in Figure 4.6, the most abundant ions in each case were
from non-covalent complexes consisting of just two nickel molecules bound
to the quadruplex. It therefore appears that after two nickel molecules are
bound to Q4, further binding events occur less readily. This may be because
the preferred binding sites for the nickel molecules are the two G-quartets at
either end of the quadruplex. Once these sites become occupied, further
binding interactions with lower affinity sites in this relatively small qDNA
molecule are inhibited because of steric hindrance and electronic factors.
Circular dichroism spectroscopy was then used to provide support for or
against the above order of nickel binding affinities towards Q4, determined
using ESI-MS. Circular dichroism spectroscopy has also been used
previously to characterise the different topologies of quadruplex DNA, and
monitor changes in its conformation upon interaction with different DNAbinding ligands.166,175-178 Each qDNA conformation gives a characteristic CD
spectrum.166,175,178,179 For example, a parallel G-quadruplex displays a
positive CD band at 260 nm, whereas an anti-parallel G-quadruplex displays
a negative CD band at this wavelength. In addition both types of quadruplex
DNA conformations give an additional positive CD band around 210 nm. The
CD spectra illustrated in Figure 4.8 show the effect of adding increasing
amounts of each of the three nickel complexes on the CD spectrum of Q4.
The spectrum of a solution containing only free Q4 exhibited major positive
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and negative CD peaks centred at 264 nm and 243 nm, respectively, which
are characteristic for parallel DNA quadruplexes.166
Inspection of Figure 4.8 shows that the addition of (8) or (14) to Q4 caused
larger changes to the ellipticity of the positive CD band, compared to that
which resulted from the addition of (11). Table 4.2 summarises the changes
to the position and ellipticity of both CD bands caused by addition of the three
nickel complexes.
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Figure 4.8: Circular dichroism spectra (200-400 nm) of solutions containing
Q4 and different ratios of nickel Schiff base complexes. (a) Q4 + (8); (b) Q4 +
(11); (c) Q4 + (14).
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Table 4.2: Effect of addition of nickel Schiff base complexes on the CD
spectrum of Q4.*
Nickel
complex

Positive CD band at 264 nm Negative CD band at 243 nm
Δλ (nm)
Δɛ (mdeg) Δλ (nm)
Δɛ (mdeg)
(8)
-0.5
-17.6
-0.9
6.1
(11)
2.9
-8.1
-1.7
2.3
(14)
-0.8
-21.0
-1.4
6.9
* All Δλ and Δε values are the difference between the values for free DNA
and those for a solution containing a DNA: nickel complex ratio of 1:9.
Negative Δλ values indicate a blue shift; positive values indicate a red shift.
Δε values are the difference between εmax for this CD band for the solution
containing no metal complex, and εmax for the same CD band for the solution
with the highest DNA: nickel complex ratio.

Inspection of Table 4.2 shows that addition of 9 equivalents of (14) and (8)
decreased the ellipticity of the positive CD band by 21.0 and 17.6 mdeg,
respectively. In contrast, the change resulting from the addition of (11) was
only 8.1 mdeg. Although this smaller change in ellipticity is consistent with
the notion that (11) has a lower affinity towards Q4 than either of the other
nickel complexes, its addition did result in a red shift to the position of this CD
band that was greater than the blue shifts caused by (8) or (14). This
highlights the sensitivity of CD spectroscopy to subtle changes in DNA
conformation caused by the addition of isomeric complexes such as those
investigated in this thesis. The larger changes to the ellipticity of the positive
CD band caused by addition of (8) and (14) were mirrored by proportionately
larger changes also to the ellipticity of the negative CD signal. If it is assumed
that changes in ellipticity are more indicative of the overall strength of the
metal/DNA binding interactions than alterations to the positions of the CD
signals, then the order of binding affinity for the three complexes is: (14) > (8)
> (11). This sequence is very different to the overall order obtained from the
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ESI-MS experiments, with the positions of complexes (11) and (14) being
reversed. If instead the shift in position of the more intense, positive CD band
is used as a measure of the binding ability of the nickel complexes, then the
overall order of binding affinity is: (11) > (14) ≈ (8). This sequence is
essentially the same as that derived from the ESI-MS study, suggesting that
changes in position of the positive CD band, although they may be typically
small in magnitude, may more accurately reflect the extent of metal/DNA
interactions.
The significant difference in binding affinity series based on changes to the
ellipticity of the positive CD band, and the extent of non-covalent complex
formation revealed in the ESI-MS study, is perhaps not surprising as the
methods exhibit varying sensitivities to different aspects of the binding
interaction. In the case of ESI-MS, the results reflect stability of non-covalent
complexes in the gas phase, whilst the changes to the CD spectrum are the
result of changes to DNA conformation in the solution. In the absence of
qualitative or quantitative binding data obtained by applying other techniques,
it is therefore impossible to know whether ESI-MS or CD spectroscopy
provides the best overall picture of the relative DNA-binding affinity of a
group of related metal complexes.

4.2.2 DNA binding experiments performed using nickel
complexes containing the 1,2-ethylenediamine moiety

This section explores the effect of changing the position of the appended
ethyl piperidine moieties in nickel Schiff base complex (13), on the binding
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affinity of the resulting nickel complexes ((7) and (10)) towards D2 and Q4.
The structures of these three complexes are shown in Figure 4.9.

Figure 4.9: Structures of nickel Schiff base complexes containing the 1,2ethylenediamine moiety, whose binding to dsDNA and qDNA are explored in
this section.

The binding affinity of complex (13) has been examined previously,155,157 and
was found to exhibit a lower binding affinity towards both of the above DNA
molecules than the corresponding salphen complex (14). This was attributed
to the former complex having one less aromatic ring able to contribute to
interactions with the base pair stack of the double-stranded D2, or
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alternatively interact with a terminal G-quartet of Q4. It was hoped that
altering the points of attachment of the ethyl piperidine groups might facilitate
additional favourable binding interactions that compensate for these issues,
and thereby endow complexes (7) and (10) with superior DNA affinity and/or
selectivity to the complexes discussed in the previous section.
A series of ESI-MS experiments was performed using solutions containing a
1:6 ratio of each of the three nickel complexes and the dsDNA molecule D2.
Figure 4.10 shows the ESI mass spectra of these solutions. The relative
abundances of all the ions observed were then calculated and are presented
in Figure 4.11. Each of the spectra in Figure 4.10b-d shows ions at m/z
1626.2 and 1952.5, which correspond to [D2 - 6H]6- and [D2 - 5H]5-,
respectively. These ions are present in medium to high abundance in Figure
4.10c, and with low to medium abundance in Figure 4.10b and d. This
suggests that the binding affinity of these nickel complexes toward D2 is
generally less than that of nickel complexes with the 1,2-phenylenediamine
moiety at the “top” of the molecule, namely (8), (11) and (14). This is because
the relative abundances of ions from free D2 in ESI-mass spectra of solutions
containing a 1:6 ratio of D2 and the latter complexes were always very low
(<22%)
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Figure 4.10: Negative ion ESI mass spectra of solutions containing D2 and
different nickel Schiff base complexes at a 1:6 ratio. (a) Free D2; (b) D2 + (7);
(c) D2 + (10); (d) D2 + (13).  = free D2;  = [D2 + (Ni)];  = [D2 + 2(Ni)]; 
= [D2 + 3(Ni)];  = [D2 + 4(Ni)].

Inspection of Figure 4.10 shows that the abundances of ions from free DNA
followed the order: (13) < (7) < (10). This suggests that the order of relative
DNA binding affinities is the opposite sequence; namely (10) < (7) < (13).
Further evidence for the conclusion that (13) has the highest affinity towards
D2 of these complexes is provided by Figure 4.11, which shows that the
relative abundances of ions from [D2 + 2(Ni)] were highest for this nickel
complex. Furthermore, (13) was the only nickel complex to give rise to ions of
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significant abundance from non-covalent complexes containing three bound
nickel molecules.
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Figure 4.11: Relative abundances of ions from free DNA and different noncovalent complexes in spectra of solutions containing D2 and different nickel
Schiff base complexes at a 1:6 ratio.

Examination of Figure 4.11 also provides evidence that (10) has the lowest
affinity towards D2 of the three nickel complexes. Foremost amongst this is
the observation that the relative abundance of ions from free D2 is greater
than that of any of the non-covalent complexes present, only in the case of
the spectrum obtained from the solution containing (10). In addition, the
relative abundances of ions from [D2 + (10)] and [D2 + 2(10)] were both
significantly less than that for the corresponding ions arising from noncovalent complexes containing (7). Confirmation of the lower affinity of
complex (10) towards D2, compared to that exhibited by (13), is also
provided by the data in Figure 4.11. In particular, the relative abundance of
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ions from [D2 + 2(10)] is much lower than that of ions from [D2 + 2(13)].
Furthermore, the absence of ions from non-covalent complexes of the type
[D2 + 3(10)] also supports this conclusion.
The results presented in Figure 4.10 and Figure 4.11 show that binding
affinity towards D2 was not enhanced by changing the position of the ethyl
piperidine groups from those they occupy in complex (13). This is the same
conclusion as that reached previously for complexes containing the
phenylenediamine moiety in the top region of the Schiff base ligand,
suggesting that the 4-position may be generally the optimal location for these
substituents.
In order to provide further support for the above conclusions, CD spectra
were obtained of solutions containing different ratios of (7), (10) or (13), and
D2, and are presented in Figure 4.12. Inspection of Figure 4.12b and c
shows that the addition of either (10) or (13) to D2 caused no significant
changes to the CD spectrum of D2. These observations suggest that (10)
and (13) do not interact to a notable extent with this dsDNA molecule. This
conclusion contrasts markedly with that based on the results of the ESI-MS
study presented earlier, which suggests that (13) had the greatest ability of
the three nickel complexes to form non-covalent complexes with dsDNA. This
apparent dichotomy in the results may be a reflection of the two experimental
techniques used being more sensitive to different aspects of the metal
complex/DNA interaction, as outlined earlier in this chapter, and commented
on by others. For example, Davis et al. found that CD experiments
sometimes suggest different trends in DNA-binding affinity for nickel
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complexes, to those indicated by ESI-MS studies.156 These researchers
reported that mass spectral studies suggested that nickel salphen complex
(14) binds to D2 to a significant extent, however, the addition of this complex
to D2 caused no significant changes to the CD spectrum of the nucleic acid.
This may be because electrostatic interactions are well-maintained in the gas
phase relative to hydrophobic interactions, and binding modes in which one
type of interaction predominates over others may result in a bias in ESI-MS
experiments.180 CD spectra show only bulk effects and give no information
about the different complexes that may be present in a mixture.
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Figure 4.12: Circular dichroism spectra (200-400 nm) of solutions containing
D2 and different ratios of nickel Schiff base complexes. (a) D2 + (7); (b) D2 +
(10); (c) D2 + (13).
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Figure 4.12a shows that addition of complex (7) had the greatest effect on
the ellipticity of three major CD bands. For example, addition of 9 equivalents
of (7) increased the ellipticity of the negative CD band by 3.3 mdeg. The
contrast been the effect of addition of complex (7) on the CD spectrum of D2,
and that caused by addition of either (10) or (13), is summarised by Table
4.3, which presents the changes in wavelength and ellipticity of the two
principal CD bands caused by addition of the three nickel complexes.

Table 4.3: Effect of addition of nickel Schiff base complexes on the CD
spectrum of D2.*
Nickel
complex

Positive CD band at 282 nm Negative CD band at 252 nm
Δλ (nm)
Δɛ (mdeg)
Δλ (nm)
Δɛ (mdeg)
(7)
-2.8
-1.4
-2.6
3.3
(10)
1.1
-0.8
2.2
-1.2
(13)
-0.6
-0.7
2.1
1.2
* All Δλ and Δε values are the difference between the values for free DNA
and those for a solution containing a DNA:nickel complex ratio of 1:9.
Negative Δλ values indicate a blue shift; positive values indicate a red shift.
Δε values are the difference between εmax for this CD band for the solution
containing no metal complex, and εmax for the same CD band for the solution
with the highest DNA:nickel complex ratio.

The variation in the magnitude of the changes in ellipticity of the CD bands at
252 and 282 nm suggests the following binding affinity order: (7) > (13) ≈
(10). The difference between this binding affinity sequence, and that derived
by ESI-MS, can be explained by proposing that the location of the ethyl
piperidine moieties in complex (7) enables it to participate in slightly different
modes of DNA binding to that employed by (13) and (10). Furthermore, the
binding mode used by (7) results in larger changes to the overall DNA
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conformation and therefore the CD spectrum, but does not afford noncovalent complexes sufficient stability to withstand the environment of the
mass spectrometer. Despite the apparent differences in binding affinity order
that the two techniques suggest for complexes (7) and (13), both methods
give results consistent with the conclusion that complex (10) has the lowest
affinity towards D2 of the three nickel complexes.
A series of ESI-MS experiments was also performed using solutions
containing a 1:6 ratio of the tetramolecular quadruplex Q4, and either (7),
(10) or (13). These experiments were performed to provide the information
required to make an assessment of whether altering the position of the ethyl
piperidine groups favourably affects the selectivity of the nickel complexes for
qDNA over dsDNA. Figure 4.13 shows the mass spectra obtained of the
above solutions.
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Figure 4.13: Negative ion ESI mass spectra of solutions containing Q4 and
different nickel Schiff base complexes at a 1:6 ratio. (a) Free Q4; (b) Q4 +
(7); (c) Q4 + (10); (d) Q4 + (13).  = free Q4;  = [Q4 + (Ni)];  = [Q4 +
2(Ni)];  = [Q4 + 3(Ni)];  = [Q4 + 4(Ni)].

After addition of the nickel Schiff base complexes, the only spectrum to show
ions from free DNA was that presented in Figure 4.13c, which was of a
solution containing a 1:6 ratio of Q4 and (10). This observation, combined
with the much lower abundance of ions from non-covalent complexes
consisting of [Q4 + 2(10)], compared to that of analogous ions in the spectra
shown in Figure 4.13b and d, indicates that (10) has the lowest affinity of
these three nickel complexes for this particular tetramolecular quadruplex.
Reinforcing this conclusion is the observation that the most abundant ions in
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Figure 4.13c are from [Q4 + (10)]. In contrast, the most abundant ions in
Figure 4.13b and d are from [Q4 + 2(7)] and [Q4 + 2(13)], respectively.
Furthermore, Figure 4.13b and d both show ions of low to medium
abundance at m/z 2358.1, from [Q4 + 3(Ni)], which are of greater abundance
than the corresponding ions in the spectrum of the solution containing (10).
Comparison of Figure 4.13b and d does not, however, enable a
determination as to which of complexes (7) and (13) has the highest affinity
towards Q4 to be readily made. Therefore in order to address this question
the relative abundances of each of the ions present in Figure 4.13b-d were
calculated, and are presented in Figure 4.14.
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Figure 4.14: Relative abundances of ions in ESI mass spectra of solutions
containing Q4 and different nickel Schiff base complexes at a 1:6 ratio.
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Examination of Figure 4.14 shows that while the abundance of ions from [Q4
+ (Ni)] is perhaps slightly greater for (7) than (13), the opposite was true for
ions arising from non-covalent complexes of the type [Q4 + 3(Ni)]. These
observations, together with the very similar relative abundances of ions from
[Q4 + 2 (Ni)], for complex (7) and (13), suggests that the affinity of these two
nickel complexes towards Q4 are very similar. The preference of Q4 to bind
two molecules of (7) and (13) is striking, and was also evident in Figure 4.6
based on the results presented in Figure 4.14, the overall order of binding
affinity for these three complexes is: (13) ≈ (7) > (10). This is very similar to
the order of DNA affinities obtained for these nickel complexes from ESI-MS
binding studies involving the dsDNA molecule D2.
It is possible to gain insight into the DNA-binding selectivity of the three nickel
complexes by comparing the relative abundance data present in Figure 4.11
and Figure 4.14. This reveals that the most abundant non-covalent
complexes present in the spectra of solutions containing a 1:6 ratio of either
D2 or Q4, and (10) are from [D2 + (10)] and [Q4 + (10)], respectively. This
suggests that the binding affinity of (10) towards Q4 and D2 is quite similar.
In contrast, complexes (7) and (13) appear to have a preference for binding
to Q4 over D2, as the relative abundances of ions attributable to noncovalent complexes containing one or more molecules of (7) or (13) bound to
Q4 are higher than for the analogous non-covalent complexes involving D2.
This indicates that both (7) and (13) display a degree of binding selectivity in
favour of Q4, which is greater than that exhibited by (10). Furthermore, the
results obtained from the ESI-MS studies performed with both types of DNA
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indicate that moving the ethyl piperidine groups from their locations in
complex (13), to their positions in (7) did not improve selectivity towards Q4.
In order to further explore the effects of changing the location of the ethyl
piperidine groups on DNA selectivity, CD spectra were obtained of solutions
containing different ratios of Q4 and either (7), (10) or (13). These spectra
are presented in Figure 4.15, while the changes in position and ellipticity of
the CD bands are compiled in Table 4.4.
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Figure 4.15: Circular dichroism spectra (200-400 nm) of solutions containing
Q4 and different ratios of nickel Schiff base complexes. (a) Q4 + (7); (b) Q4 +
(10); (c) Q4 + (13).
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Table 4.4: Effect of addition of nickel Schiff base complexes on the CD
spectrum of Q4.*
Nickel
complex

Positive CD band at 264 nm Negative CD band at 243 nm
Δλ (nm)
Δɛ (mdeg)
Δλ (nm)
Δɛ (mdeg)
(7)
-1.2
-9.2
-0.4
3.0
(10)
0.9
-1.7
-0.8
0.0
(13)
-0.1
-1.6
-0.3
1.3
* All Δλ and Δε values are the difference between the values for free DNA
and those for a solution containing a DNA:nickel complex ratio of 1:9.
Negative Δλ values indicate a blue shift; positive values indicate a red shift.
Δε values are the difference between εmax for this CD band for the solution
containing no metal complex, and εmax for the same CD band for the solution
with the highest DNA:nickel complex ratio.

Inspection of the results shows that the addition of either (10) or (13) to Q4
had essentially no effect on the CD spectrum of the DNA. The absence of
notable changes to the CD spectrum is perhaps not too surprising in the case
of complex (10), as it showed the poorest ability to form non-covalent
complexes with this quadruplex molecule in ESI-MS experiments. In contrast,
complex (13) was shown to exhibit the highest affinity towards Q4, thereby
making the absence of any effect it has on the CD spectrum of this
quadruplex another example of a surprising result that can best be explained
by reflecting on the differing abilities of the two analytical methods to
differentiate complexes employing different binding modes.
Figure 4.15a shows that the effect of addition of (7) on the CD spectrum of
Q4 is greater than that elicited by the other two complexes. Most notably, the
ellipticity of the positive CD band decreased by 9.2 mdeg, which was by far
the largest change observed. Complex (7) also had the largest effect on the
CD spectrum of D2 (Figure 4.12). This suggests that complex (7) is able to
interact in one or more ways with both Q4 and D2 that are different to that
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used by other nickel complexes, and which results in the largest changes to
the conformation of these DNA molecules.

4.2.3 DNA binding experiments performed using nickel
complexes containing the meso-1,2-diphenylethylenediamine moiety

Previous work showed that nickel complex (15), containing the meso-1,2diphenylethylenediamine moiety, exhibited a significant degree of DNA
selectivity as a consequence of exhibiting a comparable ability to most other
complexes of this type to bind to Q4, but essentially no ability to interact with
D2.156 It was therefore decided to synthesise complex (12), in which the two
ethyl piperidine groups are located in different positions to those they occupy
in (15), to see if this complex might retain the ability to bind to dsDNA
conferred by the diamine moiety in the “top” of the Schiff base ligand, but
more avidly bind to Q4. This section compares the DNA-binding properties of
(12) and (15), whose structures are shown in Figure 4.16. It was initially
hoped to also be able to extend this investigation to the third isomer, complex
(9). However, the latter complex could not be obtained in sufficient purity to
facilitate these additional studies.

129

Figure 4.16: Structures of nickel Schiff base complexes containing the meso1,2-diphenylethylenediamine moiety, whose binding to dsDNA and qDNA are
explored in this section.

Initially ESI mass spectra were obtained of solutions containing a 1:6 ratio of
D2 and the two different nickel complexes (Figure 4.17). Both spectra
showed ions with high abundance at m/z 1626.6 from [D2 - 6H]6-, as well as
ions of low to medium abundance at 1952.0 from [D2 - 5H]5-. In fact the
spectra in Figure 4.17b and c are very similar to each other, and to the
spectrum of the solution containing only D2, which is shown in Figure 4.17a.
These observations support the view that neither (12) or (15) have significant
affinity towards D2. This view is reinforced by the observation of ions of only
low to very low abundance which can be attributed to the formation of noncovalent complexes between the nickel molecules and D2, and is consistent
with the results of a published investigation into the affinity of complex (15)
towards this dsDNA sequence.156
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Figure 4.17: Negative ion ESI mass spectra of solutions containing D2 and
different nickel Schiff base complexes at a 1:6 ratio. (a) Free D2; (b) D2 +
(12); (c) D2 + (15).  = free D2;  = [D2 + (Ni)];  = [D2 + 2(Ni)].

The results of the present study therefore both confirm the results of the
previous study which showed that (15) exhibits very low affinity towards
D2,156 and also suggests that changing the position of the ethyl piperidine
groups on the Schiff base ligand has little impact on the ability to bind to this
type of nucleic acid molecule. Instead the results reaffirm the view that the
presence of the non-planar meso-1,2-diphenylethylenediamine moiety
prohibits strong interactions with D2, perhaps by hindering the approach of
these molecule to the dsDNA to bind via partial intercalation or groove
binding.
In order to provide further evidence that changing the position of the ethyl
piperidine groups in (15) does not significantly affect affinity of the nickel
molecule towards D2, CD spectra were obtained of solutions containing
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different ratios of D2 and either (12) or (15). Figure 4.18 shows the CD
spectra obtained of these solutions, while Table 4.5 present the changes in
position and ellipticity of the individual CD bands of the nucleic acid caused
by addition of 9 equivalents of the nickel complexes.
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Figure 4.18: Circular dichroism spectra (200-400 nm) of solutions containing
D2 and different ratios of nickel Schiff base complexes. (a) D2 + (12); (b) D2
+ (15).

Table 4.5: Effect of addition of nickel Schiff base complexes on the CD
spectrum of D2.*
Nickel
Positive CD band at 282 nm Negative CD band at 252 nm
complex
Δλ (nm)
Δɛ (mdeg)
Δλ (nm)
Δɛ (mdeg)
(12)
0.7
-1.2
0.6
0.9
(15)
1.4
-3.2
2.4
3.9
* All Δλ and Δε values are the difference between the values for free DNA
and those for a solution containing a DNA:nickel complex ratio of 1:9.
Negative Δλ values indicate a blue shift; positive values indicate a red shift.
Δε values are the difference between εmax for this CD band for the solution
containing no metal complex, and εmax for the same CD band for the solution
with the highest DNA:nickel complex ratio.

Addition of complex (12) had only a minor effect on the CD spectrum of D2,
as expected, since this complex showed little ability to bind to D2 in the ESI132

MS experiments. In contrast, the addition of (15) did have a significant effect
on both major CD bands of the nucleic acid. This was a surprising result, as
(15) also showed a very poor ability to form non-covalent complexes in the
solutions used to obtain ESI mass spectra. The observation that complex
(15) did cause significant changes to the CD spectrum of D2, whereas
addition of (12) did not, again highlights the high degree of sensitivity of CD
spectroscopy to what are perhaps small differences in how different metal
complexes affect the conformation of nucleic acids. It is worthwhile noting
that the change in ellipticity of the positive band of D2 caused by addition of
(15) was greater than that caused by addition of any of the other nickel
complexes investigated in this study. For example, the decrease in ellipticity
of the positive CD band of D2 caused by addition of (15) (3.2 mdeg) was
almost double that observed upon addition of the same amount of either (7),
(8), (11) or (14). Addition of (15) also resulted in a larger change to the
ellipticity of the negative CD band of D2 than that caused by any of the other
nickel complexes investigated in this thesis, with the exception of complex
(14), which resulted in an equivalent change.
The results in the previous section indicate that changing the location of the
ethyl piperidine groups from where they are situated in complex (15), to their
positions in (12), did not change the very low affinity exhibited by the former
complex towards a typical dsDNA molecule. This meant that if this change in
structure resulted in an increase in affinity towards Q4, compared to that
exhibited by (15), then complex (12) could be considered to display a greater
degree of DNA-binding selectivity.
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To investigate this possibility, ESI mass spectra were obtained of solutions
containing Q4 and either (12) or (15) at a DNA:nickel complex ratio of 1:6.
The spectrum of the solution containing Q4 and (12) (Figure 4.19b), shows
ions from free DNA with low and medium abundance at m/z 1675.4 and
2010.7, respectively. These ions do not, however, appear in the spectrum of
the solution containing Q4 and (15). This observation, combined with the
lower abundance of ions from [Q4 + 2(Ni)] in Figure 4.19b, compared to that
of analogous ions in Figure 4.19c, indicates that (12) has a slightly lower
affinity towards Q4 than (15).
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Figure 4.19: Negative ion ESI mass spectra of solutions containing Q4 and
different nickel Schiff base complexes at a 1:6 ratio. (a) Free Q4; (b) Q4 +
(12); (c) Q4 + (15).  = free Q4;  = [Q4 + (Ni)];  = [Q4 + 2(Ni)];  = [Q4 +
3(Ni)].
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The results presented in Figure 4.17 and Figure 4.19 therefore suggest that
changing the location of the ethyl piperidine groups, from where they are in
complex (12), to where they are in (15), did have a small, but favourable
effect on selectivity for Q4. In order to test this conclusion, CD spectra were
obtained of solutions containing different ratios of either (12) or (15) and Q4,
and are presented in Figure 4.20. Table 4.6 summarises the changes to the
position and ellipticity of both CD bands caused by addition of the two nickel
complexes.
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Figure 4.20: Circular dichroism spectra (200-400 nm) of solutions containing
different ratios of Q4 and nickel Schiff base complexes. (a) Q4 + (12); (b) Q4
+ (15).

Table 4.6: Effect of addition of nickel Schiff base complexes on the CD
spectrum of Q4.*
Nickel
Positive CD band at 264 nm Negative CD band at 243 nm
complex
Δλ (nm)
Δɛ (mdeg)
Δλ (nm)
Δɛ (mdeg)
(12)
1.5
-11.8
-1.2
5.1
(15)
-1.0
-4.8
-0.7
4.1
* All Δλ and Δε values are the difference between the values for free DNA
and those for a solution containing a DNA:nickel complex ratio of 1:9.
Negative Δλ values indicate a blue shift; positive values indicate a red shift.
Δε values are the difference between εmax for this CD band for the solution
containing no metal complex, and εmax for the same CD band for the solution
with the highest DNA:nickel complex ratio.
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Figure 4.20 reveals that the addition of increasing amounts of either (12) or
(15) to a solution of Q4 resulted in small changes to the CD spectrum of the
nucleic acid. Surprisingly, it was found that the changes to the position of the
CD bands caused by addition of (12) were greater than that caused by
addition of (15) (Table 4.6). This suggests that (12) may exhibit a higher
binding affinity than (15) toward Q4, which contrasts with the conclusion
reached on the basis of the results obtained from the ESI-MS study. Most
notable was the significant decrease in ellipticity of the positive CD band of
11.8 mdeg caused by addition of 9 equivalents of (12) (Table 4.6). In
contrast, addition of (15) only changed the ellipticity of this CD band by 4.8
mdeg. This therefore represents one final example where the results
obtained from DNA-binding studies performed using the two different
instrumental methods must be interpreted with caution, as they most likely
provide information about different aspects of the metal complex/DNA
interaction.
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CHAPTER 5

CONCLUSIONS

The ability of nickel Schiff base complexes to bind selectively to quadruplex
DNA has attracted significant attention in recent years. This is a
consequence of their ease of synthesis, and the combination of structural
and electronic properties that endow upon them the ability to bind effectively
to these nucleic acid secondary structures. Previous investigations in this
area have focussed on the DNA-binding interactions of complexes such as
(13), (14) and (15), which were prepared via a two-step procedure that
involved initially the reaction between different diamines and 2,4dihydroxybenzaldehyde, in the presence of nickel(II).156,157 Subsequently the
hydroxyl groups present in the resulting compounds were derivatised using
1-(2-chloroethyl) piperidine hydrochloride to afford nickel complexes with
sufficient water solubility for studying their DNA-binding behaviour in aqueous
solution. It was shown that changing the diamine used in the initial step of the
synthetic procedure can have a significant effect on affinity towards either or
both dsDNA and qDNA.156
One aspect of the structure of the above complexes, whose effect on DNAbinding properties had not been examined previously, was the location of the
ethyl piperidine moieties on the Schiff base ligand. The current investigation
into the effect of such alterations was prompted by both the absence of
information concerning the effects of such changes, and the knowledge that
the ethyl piperidine groups have been shown to play a significant role in
interactions with quadruplex DNA structures.154 Therefore, the overall aim of
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this thesis was to use a combination of two different techniques, ESI-MS and
CD spectroscopy, to investigate the effects of varying the position of the ethyl
piperidine groups in the nickel Schiff base complexes, on their abilities to
bind to a duplex 16mer DNA molecule and a tetramolecular DNA quadruplex.
Over the course of this project five novel alkylated nickel Schiff base
complexes were prepared, which featured ethyl piperidine moieties in
different locations to those in previously studied compounds. All new
compounds were synthesised in high purity, and characterised using NMR
spectroscopy, ESI-MS and microanalysis. In addition, the solid-state
structures of two of these nickel complexes, as well as one of the precursor
complexes, were determined by single crystal X-ray diffraction methods.
ESI-MS and CD spectroscopy were both used to assess the extent of binding
interactions between the nickel complexes and DNA. In the case of ESI-MS,
it was assumed that the abundance of ions from non-covalent complexes
containing different numbers of nickel molecules bound to DNA would reflect
the extent of the binding interactions, and could be used to determine relative
orders of binding affinity. Addition of the nickel complexes in some instances
produced changes to the position and, in particular the ellipticity, of the
principal features in the CD spectra of D2 and Q4. The magnitudes of these
changes were also used to determine relative orders of binding affinity, that
were then compared to those determined from ESI mass spectra.
On some occasions both the ESI-MS and CD spectroscopic results gave
essentially the same conclusions regarding the impact of changing the
location of the ethyl piperidine moieties on DNA-binding properties. For
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example, variations in the relative abundances of ions from non-covalent
complexes observed in ESI mass spectra, and changes to the ellipticity of the
positive CD band of D2, both suggested that the affinity of complex (14) for
this DNA molecule was at least as great as, if not greater than, that of the two
isomeric molecules (8) and (11). Addition of (14) did produce a small blue
shift for this CD signal, in contrast to the red shifts observed upon addition of
the other two nickel complexes, perhaps suggesting some subtle differences
in their modes of DNA binding. Overall, however, it appeared that changing
the position of the ethyl piperidine groups from their positions in the
previously studied complex (14) had only a small effect on affinity towards
the dsDNA molecule D2.
The results of ESI-MS studies into the binding of the other two series of
nickel complexes to D2 also suggested that changing the position of the ethyl
piperidine moieties from where they are located in the two lead complexes,
((13) and (15)) did not enhance affinity towards this dsDNA molecule. For the
complexes prepared using ethylenediamine as one of the starting materials,
the relative abundances of ions from non-covalent complexes containing one
or more molecules of (13) bound to D2 was greater than that for analogous
ions containing either (7) or (10). This suggests that changing the location of
the ethyl piperidine moieties from their location in (13) was in fact detrimental
to the ability of the complex to bind to dsDNA. A different conclusion was
reached upon analysis of the changes observed to the CD spectrum of D2
when (7), (10) or (13) was added, as it was the former nickel complex which
had the greatest effect. As expected complexes (12) and (15), which were
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both

prepared

via

synthetic

routes

involving

meso-1,2-

diphenylethylenediamine as one of the starting materials, exhibited
essentially no ability to form non-covalent complexes with D2 in ESI mass
spectral experiments. This suggests that neither complex exhibits a
significant ability to bind to dsDNA. Surprisingly, however, addition of (15)
resulted in the biggest changes to the CD spectrum of D2 of any of the nickel
complexes examined.
In order to develop an understanding of the origin of variations in binding
affinities derived by the two techniques, such as those discussed above, it is
important to reflect upon differences between the two instrumental
techniques used. In the case of mass spectrometry, the spectra obtained
show ions from non-covalent complexes which have sufficient stability to
pass from the solution to the gas phase. It has been proposed that
electrostatic interactions may play an important role in maintaining noncovalent complexes during the ESI process and in the gas phase, and
therefore be a contributing factor to the differences with the DNA-binding
results obtained via the two methods.180 Essentially, two different noncovalent complexes with the same stability as reflected in an overall binding
constant, may exhibit different relative abundances of ions in ESI mass
spectra, if the contributions of electrostatic interactions to their overall stability
vary. In contrast, CD spectroscopy is uniquely sensitive to the effects that
binding of small molecules can have on the chirality of DNA molecules.
Therefore even a relatively minor component of the overall binding interaction
between a nickel molecule and D2 can result in large changes to the CD
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spectrum of the latter, or another type of DNA molecule, if the interaction
alters the helicity of the nucleic acid. It is not a requirement for such binding
interactions to survive on being transferred from solution to the gas phase, in
order for its effects to become apparent in a CD spectrum.
Differences between orders of binding affinity determined on the basis of
ESI-MS and CD experiments were even more prevalent amongst studies
conducted using the tetramolecular quadruplex Q4. The results of binding
studies performed using mass spectrometry suggested that for two of the
three series of complexes studied it was the lead nickel complex, prepared
using a synthetic pathway that employed 2,4-dihydroxybenzadehyde, which
exhibited the highest binding affinity. For the complexes containing an
ethylenediamine moiety, complex (13) showed a greater ability to form noncovalent complexes with Q4 than either (7) or (10), while for those featuring
the 1,2-meso-diphenylethylenediamine moiety in the “top” of the molecule,
complex (15) proved to have a higher affinity than (12). The results of the
binding experiments performed using CD spectroscopy yielded a different
perspective for both series of complexes. Complex (7), prepared via a
pathway that involved 2,5-dihydroxybenzaldehyde, had a bigger impact on
the CD spectrum of Q4 than either (10) or (13), mimicking the results
obtained in binding studies involving D2. Addition of (15) to a solution of Q4
did not affect the CD spectrum of the latter as much as the introduction of
(12), which was prepared using 2,3-dihydroxybenzaldehyde as one of the
initial reactants. This result is in direct contrast to what was expected on the
basis of the ESI-MS studies of these systems. The series of complexes
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containing the phenylenediamine moiety in the “top” of the Schiff base ligand
also produced different results in ESI-MS and CD experiments involving Q4.
On this occasion, the results of the CD investigation showed that the isomer
prepared using 2,4-dihydroxybenzaldehyde, complex (14), had the biggest
impact, thereby suggesting it may have the greatest binding affinity. In
contrast, the results of the ESI-MS study performed using this series of three
nickel complexes indicated that (11) was more capable of forming noncovalent complexes with Q4, than either (8) or (14). The results of ESI-MS
experiments performed using this triad of nickel complexes, and both types of
DNA molecules, suggest that (11) may have a greater degree of binding
selectivity in favour of Q4 over D2, than either of the other complexes.
However, the changes observed to the CD spectra of Q4, in particular, cast
doubt over this assessment. It should be noted that where binding is
predominantly stabilised by hydrophobic interactions, such as end-stacking
on a tetramolecular qDNA, it is thought that such interactions are either
unchanged in strength or weakened relative to electrostatic interactions. 180
End-stacking has been observed for the binding of the anthracycline,
daunomycin, to a molecule similar to Q4.115
The results of the ESI-MS investigations carried out as part of this study
suggest that, in general, changing the location of the ethyl piperidine moieties
on the Schiff base ligand did not have a great effect on affinity for either type
of DNA molecule. Most of the new nickel complexes, with the exception of
(12), showed a significant ability to form non-covalent complexes with D2 and
Q4, indicating a notable degree of binding affinity. In the case of (12), ESI
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mass spectra of solutions containing this nickel complex and D2 were almost
completely devoid of ions arising from non-covalent complexes formed
between the metal complex and dsDNA molecule. This was not unexpected
as complex (15), which also features the 1,2-meso-diphenylethylenediamine
moiety in the “top” of the Schiff base ligand, was shown previously by a
variety of methods to have a very low affinity towards dsDNA molecules.156
Incorporation of this structural unit into the Schiff base ligand therefore
appears to consistently have a far more significant impact upon DNA binding,
at least in the case of the dsDNA molecule D2, than changing the location of
the ethyl piperidine moieties.
In some instances the magnitude of changes to the CD spectrum of D2 and
Q4 were generally consistent with what would be predicted using DNA
affinities based on ESI-MS studies of the same systems. However, on many
occasions there were significant discrepancies between DNA binding
affinities based on relative ion abundances on the one hand, and the
magnitude of changes to the ellipticity of CD signals arising from DNA, on the
other. It should be noted that addition of nickel complexes resulted in
changes to both the position and ellipticity of the CD signals arising from D2
and Q4. However, the magnitude of the red and blue shifts of the CD bands
was always very small, suggesting that the strength of the overall binding
interactions may not be that great, and that this parameter is unlikely to be an
accurate measure of subtle changes in binding affinities. In contrast, on some
occasions very large changes to the ellipticity of the CD bands were
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observed, including where the results of ESI-MS investigations into the same
system did not suggest a strong overall binding interaction.
The above observations highlight that care must be taken when interpreting
in isolation the results of DNA-binding studies performed using different
techniques. ESI-MS and CD spectroscopy may be uniquely suited to
providing information about different aspects of the metal complex/DNA
interaction. CD spectroscopy can probe subtle changes in binding mode but
offers a view of only bulk solution effects. ESI-MS allows for high-throughput
screening, and is suitable for small sample sizes and allows observation of all
species present in the sample. Under some conditions, the disadvantage of
ESI-MS may be in comparing the abundances of complexes where the
relative contributions of hydrophobic versus electrostatic interactions are
vastly different, and one type predominates to a great extent over the other.
The fact that different techniques for observing snapshots of equilibria have
different advantages and disadvantages is not surprising.
It is therefore recommended that other spectroscopic techniques commonly
applied to examining metal complex/DNA interactions be used to explore the
systems presented in this thesis. Absorption spectrophotometry, which can
be used to provide a measure of the overall strength of binding interactions in
the form of a binding constant, and fluorescence resonance energy transfer
(FRET) spectroscopy, which affords this information in the form of changes to
the melting temperature of a DNA molecule, are two such methods widely
used by the bio-inorganic chemistry community for this purpose. It would be
particularly interesting to see if these methods afforded orders of binding
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affinity that match more closely those derived here using ESI-MS or CD
spectroscopy. If this were to prove to be the case, it would not necessarily
follow that the other technique should be abandoned for examining these
binding interactions. In contrast, it may allow a stronger focus to be turned to
those aspects of the overall interaction that are highlighted by different
spectroscopic methods.
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